Header Logo

DONALD BERRY

TitleProfessor
InstitutionMD Anderson
DepartmentBiostatistics
Address1400 Pressler St
Houston TX 77030-4008
vCardDownload vCard

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Campbell MJ, Wolf DM, Yau C, Brown-Swigart L, Wulfkuhle J, Gallagher IR, Zhu Z, Bolen J, Vandenberg S, Hoyt C, Mori H, Borowsky A, Sit L, Perlmutter J, Asare SM, I-SPY2 Investigators, Nanda R, Liu MC, Yee D, DeMichele AM, Hylton NM, Pusztai L, Berry DA, Hirst GL, Petricoin EF, Veer LV, Esserman L. Multi-platform biomarkers of response to an immune checkpoint inhibitor in the neoadjuvant I-SPY 2 trial for early-stage breast cancer. Cell Rep Med. 2024 Nov 19; 5(11):101799. PMID: 39510069.
      Citations:    Fields:    Translation:Humans
    2. Trentham-Dietz A, Chapman CH, Jayasekera J, Lowry KP, Heckman-Stoddard BM, Hampton JM, Caswell-Jin JL, Gangnon RE, Lu Y, Huang H, Stein S, Sun L, Gil Quessep EJ, Yang Y, Lu Y, Song J, Mu?oz DF, Li Y, Kurian AW, Kerlikowske K, O'Meara ES, Sprague BL, Tosteson ANA, Feuer EJ, Berry D, Plevritis SK, Huang X, de Koning HJ, van Ravesteyn NT, Lee SJ, Alagoz O, Schechter CB, Stout NK, Miglioretti DL, Mandelblatt JS. Collaborative Modeling to Compare Different Breast Cancer Screening Strategies: A Decision Analysis for the US Preventive Services Task Force. JAMA. 2024 06 11; 331(22):1947-1960. PMID: 38687505.
      Citations: 1     Fields:    Translation:HumansPHPublic Health
    3. Albain KS, Yau C, Petricoin EF, Wolf DM, Lang JE, Chien AJ, Haddad T, Forero-Torres A, Wallace AM, Kaplan H, Pusztai L, Euhus D, Nanda R, Elias AD, Clark AS, Godellas C, Boughey JC, Isaacs C, Tripathy D, Lu J, Yung RL, Gallagher RI, Wulfkuhle JD, Brown-Swigart L, Krings G, Chen YY, Potter DA, Stringer-Reasor E, Blair S, Asare SM, Wilson A, Hirst GL, Singhrao R, Buxton M, Clennell JL, Sanil A, Berry S, Asare AL, Matthews JB, DeMichele AM, Hylton NM, Melisko M, Perlmutter J, Rugo HS, Symmans WF, Van't Veer LJ, Yee D, Berry DA, Esserman LJ. Neoadjuvant Trebananib plus Paclitaxel-based Chemotherapy for Stage II/III Breast Cancer in the Adaptively Randomized I-SPY2 Trial-Efficacy and Biomarker Discovery. Clin Cancer Res. 2024 02 16; 30(4):729-740. PMID: 38109213; PMCID: PMC10956403.
      Citations: 5     Fields:    Translation:HumansCTClinical Trials
    4. Caswell-Jin JL, Sun LP, Munoz D, Lu Y, Li Y, Huang H, Hampton JM, Song J, Jayasekera J, Schechter C, Alagoz O, Stout NK, Trentham-Dietz A, Lee SJ, Huang X, Mandelblatt JS, Berry DA, Kurian AW, Plevritis SK. Analysis of Breast Cancer Mortality in the US-1975 to 2019. JAMA. 2024 01 16; 331(3):233-241. PMID: 38227031; PMCID: PMC10792466.
      Citations: 14     Fields:    Translation:Humans
    5. Berry DA, Dhadda S, Kanekiyo M, Li D, Swanson CJ, Irizarry M, Kramer LD, Berry SM. Lecanemab for Patients With Early Alzheimer Disease: Bayesian Analysis of a Phase 2b Dose-Finding Randomized Clinical Trial. JAMA Netw Open. 2023 04 03; 6(4):e237230. PMID: 37040116; PMCID: PMC10091161.
      Citations:    Fields:    Translation:Humans
    6. Lang JE, Forero-Torres A, Yee D, Yau C, Wolf D, Park J, Parker BA, Chien AJ, Wallace AM, Murthy R, Albain KS, Ellis ED, Beckwith H, Haley BB, Elias AD, Boughey JC, Yung RL, Isaacs C, Clark AS, Han HS, Nanda R, Khan QJ, Edmiston KK, Stringer-Reasor E, Price E, Joe B, Liu MC, Brown-Swigart L, Petricoin EF, Wulfkuhle JD, Buxton M, Clennell JL, Sanil A, Berry S, Asare SM, Wilson A, Hirst GL, Singhrao R, Asare AL, Matthews JB, Melisko M, Perlmutter J, Rugo HS, Symmans WF, van 't Veer LJ, Hylton NM, DeMichele AM, Berry DA, Esserman LJ. Safety and efficacy of HSP90 inhibitor ganetespib for neoadjuvant treatment of stage II/III breast cancer. NPJ Breast Cancer. 2022 Dec 01; 8(1):128. PMID: 36456573; PMCID: PMC9715670.
      Citations: 1     
    7. Vo HH, Fu S, Hong DS, Karp DD, Piha-Paul S, Subbiah V, Janku F, Naing A, Yap TA, Rodon J, Ajani JA, Cartwright C, Johnson A, Song IW, Beck J, Kahle M, Nogueras-Gonzalez GM, Miller V, Chao C, Vining DJ, Berry DA, Meric-Bernstam F, Tsimberidou AM. Challenges and opportunities associated with the MD Anderson IMPACT2 randomized study in precision oncology. NPJ Precis Oncol. 2022 Oct 27; 6(1):78. PMID: 36302890; PMCID: PMC9612600.
      Citations: 1     
    8. Short NJ, Fu C, Berry DA, Walter RB, Freeman SD, Hourigan CS, Huang X, Gonzalez GN, Hwang H, Qi X, Kantarjian H, Zhou S, Ravandi F. Association of hematologic response and assay sensitivity on the prognostic impact of measurable residual disease in acute myeloid leukemia: a systematic review and meta-analysis. Leukemia. 2022 12; 36(12):2817-2826. PMID: 36261575.
      Citations: 8     Fields:    Translation:Humans
    9. Saville BR, Berry DA, Berry NS, Viele K, Berry SM. The Bayesian Time Machine: Accounting for temporal drift in multi-arm platform trials. Clin Trials. 2022 10; 19(5):490-501. PMID: 35993547.
      Citations:    
    10. Wolf DM, Yau C, Wulfkuhle J, Brown-Swigart L, Gallagher RI, Lee PRE, Zhu Z, Magbanua MJ, Sayaman R, O'Grady N, Basu A, Delson A, Lu R, Braun J, I-SPY2 Investigators, Asare SM, Sit L, Matthews JB, Perlmutter J, Hylton N, Liu MC, Pohlmann P, Symmans WF, Rugo HS, Isaacs C, DeMichele AM, Yee D, Berry DA, Pusztai L, Petricoin EF, Hirst GL, Esserman LJ, van 't Veer LJ, Copp? JP. Redefining breast cancer subtypes to guide treatment prioritization and maximize response: Predictive biomarkers across 10 cancer therapies. Cancer Cell. 2022 06 13; 40(6):609-623.e6. PMID: 35623341; PMCID: PMC9426306.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    11. Marczyk M, Mrukwa A, Yau C, Wolf D, Chen YY, Balassanian R, Nanda R, Parker BA, Krings G, Sattar H, Zeck JC, Albain KS, Boughey JC, Liu MC, Elias AD, Clark AS, Venters SJ, Shad S, Basu A, Asare SM, Buxton M, Asare AL, Rugo HS, Perlmutter J, DeMichele AM, Yee D, Berry DA, Veer LV, Symmans WF, Esserman L, Pusztai L, I-SPY Consortium. Treatment Efficacy Score-continuous residual cancer burden-based metric to compare neoadjuvant chemotherapy efficacy between randomized trial arms in breast cancer trials. Ann Oncol. 2022 08; 33(8):814-823. PMID: 35513244.
      Citations:    Fields:    
    12. Broglio K, Meurer WJ, Durkalski V, Pauls Q, Connor J, Berry D, Lewis RJ, Johnston KC, Barsan WG. Comparison of Bayesian vs Frequentist Adaptive Trial Design in the Stroke Hyperglycemia Insulin Network Effort Trial. JAMA Netw Open. 2022 05 02; 5(5):e2211616. PMID: 35544137; PMCID: PMC9096598.
      Citations:    Fields:    Translation:Humans
    13. Singh K, Batich KA, Wen PY, Tan AC, Bagley SJ, Lim M, Platten M, Colman H, Ashley DM, Chang SM, Rahman R, Galanis E, Mansouri A, Puduvalli VK, Reardon DA, Sahebjam S, Sampson JH, Simes J, Berry DA, Zadeh G, Cloughesy TF, Mehta MP, Piantadosi S, Heimberger AB, Khasraw M, Weller M. Designing Clinical Trials for Combination Immunotherapy: A Framework for Glioblastoma. Clin Cancer Res. 2022 02 15; 28(4):585-593. PMID: 34561270; PMCID: PMC9306329.
      Citations: 2     Fields:    Translation:Humans
    14. Clark AS, Yau C, Wolf DM, Petricoin EF, van 't Veer LJ, Yee D, Moulder SL, Wallace AM, Chien AJ, Isaacs C, Boughey JC, Albain KS, Kemmer K, Haley BB, Han HS, Forero-Torres A, Elias A, Lang JE, Ellis ED, Yung R, Tripathy D, Nanda R, Wulfkuhle JD, Brown-Swigart L, Gallagher RI, Helsten T, Roesch E, Ewing CA, Alvarado M, Crane EP, Buxton M, Clennell JL, Paoloni M, Asare SM, Wilson A, Hirst GL, Singhrao R, Steeg K, Asare A, Matthews JB, Berry S, Sanil A, Melisko M, Perlmutter J, Rugo HS, Schwab RB, Symmans WF, Hylton NM, Berry DA, Esserman LJ, DeMichele AM. Neoadjuvant T-DM1/pertuzumab and paclitaxel/trastuzumab/pertuzumab for HER2+ breast cancer in the adaptively randomized I-SPY2 trial. Nat Commun. 2021 11 05; 12(1):6428. PMID: 34741023; PMCID: PMC8571284.
      Citations: 4     Fields:    Translation:Humans
    15. Symmans WF, Yau C, Chen YY, Balassanian R, Klein ME, Pusztai L, Nanda R, Parker BA, Datnow B, Krings G, Wei S, Feldman MD, Duan X, Chen B, Sattar H, Khazai L, Zeck JC, Sams S, Mhawech-Fauceglia P, Rendi M, Sahoo S, Ocal IT, Fan F, LeBeau LG, Vinh T, Troxell ML, Chien AJ, Wallace AM, Forero-Torres A, Ellis E, Albain KS, Murthy RK, Boughey JC, Liu MC, Haley BB, Elias AD, Clark AS, Kemmer K, Isaacs C, Lang JE, Han HS, Edmiston K, Viscusi RK, Northfelt DW, Khan QJ, Leyland-Jones B, Venters SJ, Shad S, Matthews JB, Asare SM, Buxton M, Asare AL, Rugo HS, Schwab RB, Helsten T, Hylton NM, van 't Veer L, Perlmutter J, DeMichele AM, Yee D, Berry DA, Esserman LJ. Assessment of Residual Cancer Burden and Event-Free Survival in Neoadjuvant Treatment for High-risk Breast Cancer: An Analysis of Data From the I-SPY2 Randomized Clinical Trial. JAMA Oncol. 2021 Nov 01; 7(11):1654-1663. PMID: 34529000; PMCID: PMC8446908.
      Citations: 3     Fields:    Translation:Humans
    16. Yee D, Isaacs C, Wolf DM, Yau C, Haluska P, Giridhar KV, Forero-Torres A, Jo Chien A, Wallace AM, Pusztai L, Albain KS, Ellis ED, Beckwith H, Haley BB, Elias AD, Boughey JC, Kemmer K, Yung RL, Pohlmann PR, Tripathy D, Clark AS, Han HS, Nanda R, Khan QJ, Edmiston KK, Petricoin EF, Stringer-Reasor E, Falkson CI, Majure M, Mukhtar RA, Helsten TL, Moulder SL, Robinson PA, Wulfkuhle JD, Brown-Swigart L, Buxton M, Clennell JL, Paoloni M, Sanil A, Berry S, Asare SM, Wilson A, Hirst GL, Singhrao R, Asare AL, Matthews JB, Hylton NM, DeMichele A, Melisko M, Perlmutter J, Rugo HS, Fraser Symmans W, Van't Veer LJ, Berry DA, Esserman LJ. Ganitumab and metformin plus standard neoadjuvant therapy in stage 2/3 breast cancer. NPJ Breast Cancer. 2021 Oct 05; 7(1):131. PMID: 34611148; PMCID: PMC8492731.
      Citations: 2     
    17. Chang JY, Mehran RJ, Feng L, Verma V, Liao Z, Welsh JW, Lin SH, O'Reilly MS, Jeter MD, Balter PA, McRae SE, Berry D, Heymach JV, Roth JA, STARS Lung Cancer Trials Group. Stereotactic ablative radiotherapy for operable stage I non-small-cell lung cancer (revised STARS): long-term results of a single-arm, prospective trial with prespecified comparison to surgery. Lancet Oncol. 2021 10; 22(10):1448-1457. PMID: 34529930; PMCID: PMC8521627.
      Citations: 16     Fields:    Translation:HumansCTClinical Trials
    18. Hergenroeder GW, Yokobori S, Choi HA, Schmitt K, Detry MA, Schmitt LH, McGlothlin A, Puccio AM, Jagid J, Kuroda Y, Nakamura Y, Suehiro E, Ahmad F, Viele K, Wilde EA, McCauley SR, Kitagawa RS, Temkin NR, Timmons SD, Diringer MN, Dash PK, Bullock R, Okonkwo DO, Berry DA, Kim DH. Hypothermia for Patients Requiring Evacuation of Subdural Hematoma: A Multicenter Randomized Clinical Trial. Neurocrit Care. 2022 04; 36(2):560-572. PMID: 34518968; PMCID: PMC8964656.
      Citations:    Fields:    Translation:Humans
    19. Onishi N, Li W, Newitt DC, Harnish RJ, Strand F, Nguyen AA, Arasu VA, Gibbs J, Jones EF, Wilmes LJ, Kornak J, Joe BN, Price ER, Ojeda-Fournier H, Eghtedari M, Zamora KW, Woodard S, Umphrey HR, Nelson MT, Church AL, Bolan PJ, Kuritza T, Ward K, Morley K, Wolverton D, Fountain K, Lopez Paniagua D, Hardesty L, Brandt KR, McDonald ES, Rosen M, Kontos D, Abe H, Sheth D, Crane E, Dillis C, Sheth P, Hovanessian-Larsen L, Bang DH, Porter B, Oh KY, Jafarian N, Tudorica LA, Niell B, Drukteinis J, Newell MS, Giurescu ME, Berman E, Lehman CD, Partridge SC, Fitzpatrick KA, Borders MH, Yang WT, Dogan B, Goudreau SH, Chenevert T, Yau C, DeMichele A, Berry DA, Esserman LJ, Hylton NM. Breast MRI during Neoadjuvant Chemotherapy: Lack of Background Parenchymal Enhancement Suppression and Inferior Treatment Response. Radiology. 2021 11; 301(2):295-308. PMID: 34427465; PMCID: PMC8574064.
      Citations: 1     Fields:    Translation:Humans
    20. Berry DA, Ip A, Lewis BE, Berry SM, Berry NS, MrKulic M, Gadalla V, Sat B, Wright K, Serna M, Unawane R, Trpeski K, Koropsak M, Kaur P, Sica Z, McConnell A, Bednarz U, Marafelias M, Goy AH, Pecora AL, Sawczuk IS, Goldberg SL. Development and validation of a prognostic 40-day mortality risk model among hospitalized patients with COVID-19. PLoS One. 2021; 16(7):e0255228. PMID: 34329317; PMCID: PMC8323891.
      Citations: 2     Fields:    Translation:HumansCells
    21. Pusztai L, Yau C, Wolf DM, Han HS, Du L, Wallace AM, String-Reasor E, Boughey JC, Chien AJ, Elias AD, Beckwith H, Nanda R, Albain KS, Clark AS, Kemmer K, Kalinsky K, Isaacs C, Thomas A, Shatsky R, Helsten TL, Forero-Torres A, Liu MC, Brown-Swigart L, Petricoin EF, Wulfkuhle JD, Asare SM, Wilson A, Singhrao R, Sit L, Hirst GL, Berry S, Sanil A, Asare AL, Matthews JB, Perlmutter J, Melisko M, Rugo HS, Schwab RB, Symmans WF, Yee D, Van't Veer LJ, Hylton NM, DeMichele AM, Berry DA, Esserman LJ. Durvalumab with olaparib and paclitaxel for high-risk HER2-negative stage II/III breast cancer: Results from the adaptively randomized I-SPY2 trial. Cancer Cell. 2021 07 12; 39(7):989-998.e5. PMID: 34143979; PMCID: PMC11064785.
      Citations: 11     Fields:    Translation:HumansCTClinical Trials
    22. Tsimberidou AM, Hong DS, Fu S, Karp DD, Piha-Paul S, Kies MS, Ravi V, Subbiah V, Patel SM, Tu SM, Janku F, Heymach J, Johnson A, Cartwright C, Zhao L, Zhang J, Berry DA, Vining DJ, Futreal A, Miller VA, Meric-Bernstam F. Precision medicine: preliminary results from the Initiative for Molecular Profiling and Advanced Cancer Therapy 2 (IMPACT2) study. NPJ Precis Oncol. 2021 Mar 19; 5(1):21. PMID: 33742104; PMCID: PMC7979841.
      Citations: 2     
    23. Abraham JP, Magee D, Cremolini C, Antoniotti C, Halbert DD, Xiu J, Stafford P, Berry DA, Oberley MJ, Shields AF, Marshall JL, Salem ME, Falcone A, Grothey A, Hall MJ, Venook AP, Lenz HJ, Helmstetter A, Korn WM, Spetzler DB. Clinical Validation of a Machine-learning-derived Signature Predictive of Outcomes from First-line Oxaliplatin-based Chemotherapy in Advanced Colorectal Cancer. Clin Cancer Res. 2021 02 15; 27(4):1174-1183. PMID: 33293373.
      Citations: 8     Fields:    Translation:Humans
    24. Short NJ, Zhou S, Fu C, Berry DA, Walter RB, Freeman SD, Hourigan CS, Huang X, Nogueras Gonzalez G, Hwang H, Qi X, Kantarjian H, Ravandi F. Association of Measurable Residual Disease With Survival Outcomes in Patients With Acute Myeloid Leukemia: A Systematic Review and Meta-analysis. JAMA Oncol. 2020 Dec 01; 6(12):1890-1899. PMID: 33030517; PMCID: PMC7545346.
      Citations: 30     Fields:    Translation:Humans
    25. Mueller KL, Theoret MR, Lemery SJ, Amiri-Kordestani L, Ariyan CE, Atkins MB, Berry DA, Blank CU, DeMichele AM, Forde PM, Ibrahim N, Keegan P, Mitchell TC, Moss RA, Robert C, Sridhara R, Taube JM, Tetzlaff MT, Wargo JA, Flaherty KT, Kaplan MJ, Topalian SL, Ward AF, Hurlbert MS. Neoadjuvant Therapy for Melanoma: A U.S. Food and Drug Administration-Melanoma Research Alliance Public Workshop. Clin Cancer Res. 2021 01 15; 27(2):394-401. PMID: 33188142.
      Citations: 2     Fields:    Translation:Humans
    26. Fernandez-Martinez A, Krop IE, Hillman DW, Polley MY, Parker JS, Huebner L, Hoadley KA, Shepherd J, Tolaney S, Henry NL, Dang C, Harris L, Berry D, Hahn O, Hudis C, Winer E, Partridge A, Perou CM, Carey LA. Survival, Pathologic Response, and Genomics in CALGB 40601 (Alliance), a Neoadjuvant Phase III Trial of Paclitaxel-Trastuzumab With or Without Lapatinib in HER2-Positive Breast Cancer. J Clin Oncol. 2020 12 10; 38(35):4184-4193. PMID: 33095682; PMCID: PMC7723687.
      Citations: 18     Fields:    Translation:HumansCellsCTClinical Trials
    27. I-SPY2 Trial Consortium, Yee D, DeMichele AM, Yau C, Isaacs C, Symmans WF, Albain KS, Chen YY, Krings G, Wei S, Harada S, Datnow B, Fadare O, Klein M, Pambuccian S, Chen B, Adamson K, Sams S, Mhawech-Fauceglia P, Magliocco A, Feldman M, Rendi M, Sattar H, Zeck J, Ocal IT, Tawfik O, LeBeau LG, Sahoo S, Vinh T, Chien AJ, Forero-Torres A, Stringer-Reasor E, Wallace AM, Pusztai L, Boughey JC, Ellis ED, Elias AD, Lu J, Lang JE, Han HS, Clark AS, Nanda R, Northfelt DW, Khan QJ, Viscusi RK, Euhus DM, Edmiston KK, Chui SY, Kemmer K, Park JW, Liu MC, Olopade O, Leyland-Jones B, Tripathy D, Moulder SL, Rugo HS, Schwab R, Lo S, Helsten T, Beckwith H, Haugen P, Hylton NM, Van't Veer LJ, Perlmutter J, Melisko ME, Wilson A, Peterson G, Asare AL, Buxton MB, Paoloni M, Clennell JL, Hirst GL, Singhrao R, Steeg K, Matthews JB, Asare SM, Sanil A, Berry SM, Esserman LJ, Berry DA. Association of Event-Free and Distant Recurrence-Free Survival With Individual-Level Pathologic Complete Response in Neoadjuvant Treatment of Stages 2 and 3 Breast Cancer: Three-Year Follow-up Analysis for the I-SPY2 Adaptively Randomized Clinical Trial. JAMA Oncol. 2020 09 01; 6(9):1355-1362. PMID: 32701140; PMCID: PMC7378873.
      Citations: 22     Fields:    Translation:Humans
    28. Ip A, Berry DA, Hansen E, Goy AH, Pecora AL, Sinclaire BA, Bednarz U, Marafelias M, Berry SM, Berry NS, Mathura S, Sawczuk IS, Biran N, Go RC, Sperber S, Piwoz JA, Balani B, Cicogna C, Sebti R, Zuckerman J, Rose KM, Tank L, Jacobs LG, Korcak J, Timmapuri SL, Underwood JP, Sugalski G, Barsky C, Varga DW, Asif A, Landolfi JC, Goldberg SL. Hydroxychloroquine and tocilizumab therapy in COVID-19 patients-An observational study. PLoS One. 2020; 15(8):e0237693. PMID: 32790733; PMCID: PMC7425928.
      Citations: 57     Fields:    Translation:HumansCellsPHPublic Health
    29. Xie W, Regan MM, Buyse M, Halabi S, Kantoff PW, Sartor O, Soule H, Berry D, Clarke N, Collette L, D'Amico A, Lourenco RA, Dignam J, Eisenberger M, James N, Fizazi K, Gillessen S, Loriot Y, Mottet N, Parulekar W, Sandler H, Spratt DE, Sydes MR, Williams S, Sweeney CJ, ICECaP Working Group, Tombal B. Event-Free Survival, a Prostate-Specific Antigen-Based Composite End Point, Is Not a Surrogate for Overall Survival in Men With Localized Prostate Cancer Treated With Radiation. J Clin Oncol. 2020 09 10; 38(26):3032-3041. PMID: 32552276; PMCID: PMC8265328.
      Citations: 5     Fields:    Translation:Humans
    30. Nanda R, Liu MC, Yau C, Shatsky R, Pusztai L, Wallace A, Chien AJ, Forero-Torres A, Ellis E, Han H, Clark A, Albain K, Boughey JC, Jaskowiak NT, Elias A, Isaacs C, Kemmer K, Helsten T, Majure M, Stringer-Reasor E, Parker C, Lee MC, Haddad T, Cohen RN, Asare S, Wilson A, Hirst GL, Singhrao R, Steeg K, Asare A, Matthews JB, Berry S, Sanil A, Schwab R, Symmans WF, van 't Veer L, Yee D, DeMichele A, Hylton NM, Melisko M, Perlmutter J, Rugo HS, Berry DA, Esserman LJ. Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast Cancer: An Analysis of the Ongoing Phase 2 Adaptively Randomized I-SPY2 Trial. JAMA Oncol. 2020 05 01; 6(5):676-684. PMID: 32053137; PMCID: PMC7058271.
      Citations: 126     Fields:    Translation:HumansCTClinical Trials
    31. Muss HB, Polley MC, Berry DA, Liu H, Cirrincione CT, Theodoulou M, Mauer AM, Kornblith AB, Partridge AH, Dressler LG, Cohen HJ, Kartcheske PA, Perez EA, Wolff AC, Gralow JR, Burstein HJ, Mahmood AA, Sutton LM, Magrinat G, Parker BA, Hart RD, Grenier D, Hurria A, Jatoi A, Norton L, Hudis CA, Winer EP, Carey L. Randomized Trial of Standard Adjuvant Chemotherapy Regimens Versus Capecitabine in Older Women With Early Breast Cancer: 10-Year Update of the CALGB 49907 Trial. J Clin Oncol. 2019 09 10; 37(26):2338-2348. PMID: 31339827; PMCID: PMC6900836.
      Citations: 16     Fields:    Translation:Humans
    32. Chien AJ, Tripathy D, Albain KS, Symmans WF, Rugo HS, Melisko ME, Wallace AM, Schwab R, Helsten T, Forero-Torres A, Stringer-Reasor E, Ellis ED, Kaplan HG, Nanda R, Jaskowiak N, Murthy R, Godellas C, Boughey JC, Elias AD, Haley BB, Kemmer K, Isaacs C, Clark AS, Lang JE, Lu J, Korde L, Edmiston KK, Northfelt DW, Viscusi RK, Yee D, Perlmutter J, Hylton NM, Van't Veer LJ, DeMichele A, Wilson A, Peterson G, Buxton MB, Paoloni M, Clennell J, Berry S, Matthews JB, Steeg K, Singhrao R, Hirst GL, Sanil A, Yau C, Asare SM, Berry DA, Esserman LJ, I-SPY 2 Consortium. MK-2206 and Standard Neoadjuvant Chemotherapy Improves Response in Patients With Human Epidermal Growth Factor Receptor 2-Positive and/or Hormone Receptor-Negative Breast Cancers in the I-SPY 2 Trial. J Clin Oncol. 2020 04 01; 38(10):1059-1069. PMID: 32031889; PMCID: PMC7106976.
      Citations: 22     Fields:    Translation:HumansCTClinical Trials
    33. Jayasekera J, Schechter CB, Sparano JA, Jagsi R, White J, Chapman JW, Whelan T, Anderson SJ, Fyles AW, Sauerbrei W, Zellars RC, Li Y, Song J, Huang X, Julian TB, Luta G, Berry DA, Feuer EJ, Mandelblatt J, CISNET-BOLD Collaborative Group. Effects of Radiotherapy in Early-Stage, Low-Recurrence Risk, Hormone-Sensitive Breast Cancer. J Natl Cancer Inst. 2018 12 01; 110(12):1370-1379. PMID: 30239794; PMCID: PMC6292790.
      Citations: 18     Fields:    Translation:Humans
    34. Jayasekera J, Li Y, Schechter CB, Jagsi R, Song J, White J, Luta G, Chapman JW, Feuer EJ, Zellars RC, Stout N, Julian TB, Whelan T, Huang X, Shelley Hwang E, Hopkins JO, Sparano JA, Anderson SJ, Fyles AW, Gray R, Sauerbrei W, Mandelblatt J, Berry DA, CISNET-BOLD Collaborative Group. Simulation Modeling of Cancer Clinical Trials: Application to Omitting Radiotherapy in Low-risk Breast Cancer. J Natl Cancer Inst. 2018 12 01; 110(12):1360-1369. PMID: 29718314; PMCID: PMC6292816.
      Citations: 9     Fields:    Translation:Humans
    35. Cronin KA, Berry DA. Concern Regarding Age Distribution of Breast Cancer. JAMA Surg. 2018 11 01; 153(11):1060-1061. PMID: 30046830.
      Citations:    Fields:    Translation:Humans
    36. Blumenthal GM, Bunn PA, Chaft JE, McCoach CE, Perez EA, Scagliotti GV, Carbone DP, Aerts HJWL, Aisner DL, Bergh J, Berry DA, Jarkowski A, Botwood N, Cross DAE, Diehn M, Drezner NL, Doebele RC, Blakely CM, Eberhardt WEE, Felip E, Gianni L, Keller SP, Leavey PJ, Malik S, Pignatti F, Prowell TM, Redman MW, Rizvi NA, Rosell R, Rusch V, de Ruysscher D, Schwartz LH, Sridhara R, Swisher S, Taube JM, Travis WD, Keegan P, Wiens JR, Wistuba II, Wynes MW, Hirsch FR, Kris MG, Stahel RA. Current Status and Future Perspectives on Neoadjuvant Therapy in Lung Cancer. J Thorac Oncol. 2018 Dec; 13(12):1818-1831. PMID: 30268698.
      Citations: 49     Fields:    Translation:Humans
    37. Wulfkuhle JD, Yau C, Wolf DM, Vis DJ, Gallagher RI, Brown-Swigart L, Hirst G, Voest EE, DeMichele A, Hylton N, Symmans F, Yee D, Esserman L, Berry D, Liu M, Park JW, Wessels LFA, Van't Veer L, Petricoin EF. Evaluation of the HER/PI3K/AKT Family Signaling Network as a Predictive Biomarker of Pathologic Complete Response for Patients With Breast Cancer Treated With Neratinib in the I-SPY 2 TRIAL. JCO Precis Oncol. 2018; 2. PMID: 32914002; PMCID: PMC7446527.
      Citations: 9     Fields:    
    38. Tanioka M, Fan C, Parker JS, Hoadley KA, Hu Z, Li Y, Hyslop TM, Pitcher BN, Soloway MG, Spears PA, Henry LN, Tolaney S, Dang CT, Krop IE, Harris LN, Berry DA, Mardis ER, Winer EP, Hudis CA, Carey LA, Perou CM. Integrated Analysis of RNA and DNA from the Phase III Trial CALGB 40601 Identifies Predictors of Response to Trastuzumab-Based Neoadjuvant Chemotherapy in HER2-Positive Breast Cancer. Clin Cancer Res. 2018 11 01; 24(21):5292-5304. PMID: 30037817; PMCID: PMC6214737.
      Citations: 36     Fields:    Translation:HumansCellsCTClinical Trials
    39. Plevritis SK, Berry DA, Mandelblatt JS. Contributions of Screening and Treatment to Mortality From Breast Cancer-Reply. JAMA. 2018 06 12; 319(22):2336. PMID: 29896623.
      Citations:    Fields:    Translation:HumansPHPublic Health
    40. Xu Y, Tsimberidou AM, Berry D, M?ller P. A nonparametric Bayesian basket trial design. Biom J. 2019 09; 61(5):1160-1174. PMID: 29808479; PMCID: PMC6261711.
      Citations:    Fields:    Translation:Humans
    41. Alagoz O, Berry DA, de Koning HJ, Feuer EJ, Lee SJ, Plevritis SK, Schechter CB, Stout NK, Trentham-Dietz A, Mandelblatt JS, CISNET Breast Cancer Working Group members. Introduction to the Cancer Intervention and Surveillance Modeling Network (CISNET) Breast Cancer Models. Med Decis Making. 2018 04; 38(1_suppl):3S-8S. PMID: 29554472; PMCID: PMC5862043.
      Citations: 13     Fields:    Translation:Humans
    42. Domenyuk V, Gatalica Z, Santhanam R, Wei X, Stark A, Kennedy P, Toussaint B, Levenberg S, Wang J, Xiao N, Heimberger AB, Berry DA, Barker A, Quackenbush J, Marshall JL, Poste G, Vacirca JL, Vidal GA, Schwartzberg LS, Halbert DD, Voss A, Magee D, Miglarese MR, Famulok M, Spetzler D, Greil R, Rinnerthaler G, Gampenrieder SP, Mayer G. Poly-ligand profiling differentiates trastuzumab-treated breast cancer patients according to their outcomes. Nat Commun. 2018 03 23; 9(1):1219. PMID: 29572535; PMCID: PMC5865185.
      Citations: 10     Fields:    Translation:HumansCells
    43. Plevritis SK, Munoz D, Kurian AW, Stout NK, Alagoz O, Near AM, Lee SJ, van den Broek JJ, Huang X, Schechter CB, Sprague BL, Song J, de Koning HJ, Trentham-Dietz A, van Ravesteyn NT, Gangnon R, Chandler Y, Li Y, Xu C, Ergun MA, Huang H, Berry DA, Mandelblatt JS. Association of Screening and Treatment With Breast Cancer Mortality by Molecular Subtype in US Women, 2000-2012. JAMA. 2018 01 09; 319(2):154-164. PMID: 29318276; PMCID: PMC5833658.
      Citations: 76     Fields:    Translation:Humans
    44. Berry DA, de Koning HJ, Lee SJ, Mandelblatt JS, Plevritis SK, Schechter CB, Stout NK, Trentham-Dietz A, CISNET Breast Working Group Principal Investigators. Distinguishing between CISNET model results versus CISNET models. Cancer. 2018 03 01; 124(5):1083-1084. PMID: 29278430.
      Citations:    Fields:    
    45. Guetterman TC, Fetters MD, Mawocha S, Legocki LJ, Barsan WG, Lewis RJ, Berry DA, Meurer WJ. The life cycles of six multi-center adaptive clinical trials focused on neurological emergencies developed for the Advancing Regulatory Science initiative of the National Institutes of Health and US Food and Drug Administration: Case studies from the Adaptive Designs Accelerating Promising Treatments Into Trials Project. SAGE Open Med. 2017; 5:2050312117736228. PMID: 29085638; PMCID: PMC5648086.
      Citations: 2     
    46. Wolf DM, Yau C, Sanil A, Glas A, Petricoin E, Wulfkuhle J, Severson TM, Linn S, Brown-Swigart L, Hirst G, Buxton M, DeMichele A, Hylton N, Symmans F, Yee D, Paoloni M, Esserman L, Berry D, Rugo H, Olopade O, van 't Veer L. DNA repair deficiency biomarkers and the 70-gene ultra-high risk signature as predictors of veliparib/carboplatin response in the I-SPY 2 breast cancer trial. NPJ Breast Cancer. 2017; 3:31. PMID: 28948212; PMCID: PMC5572474.
      Citations: 35     
    47. Alexander BM, Ba S, Berger MS, Berry DA, Cavenee WK, Chang SM, Cloughesy TF, Jiang T, Khasraw M, Li W, Mittman R, Poste GH, Wen PY, Yung WKA, Barker AD, GBM AGILE Network. Adaptive Global Innovative Learning Environment for Glioblastoma: GBM AGILE. Clin Cancer Res. 2018 02 15; 24(4):737-743. PMID: 28814435.
      Citations: 56     Fields:    Translation:Humans
    48. Wadhwa R, Wang X, Baladandayuthapani V, Liu B, Shiozaki H, Shimodaira Y, Lin Q, Elimova E, Hofstetter WL, Swisher SG, Rice DC, Maru DM, Kalhor N, Bhutani MS, Weston B, Lee JH, Skinner HD, Scott AW, Kaya DM, Harada K, Berry D, Song S, Ajani JA. Nuclear expression of Gli-1 is predictive of pathologic complete response to chemoradiation in trimodality treated oesophageal cancer patients. Br J Cancer. 2017 Aug 22; 117(5):648-655. PMID: 28728163; PMCID: PMC5572179.
      Citations: 13     Fields:    Translation:HumansCells
    49. Berry DA, Zhou S, Higley H, Mukundan L, Fu S, Reaman GH, Wood BL, Kelloff GJ, Jessup JM, Radich JP. Association of Minimal Residual Disease With Clinical Outcome in Pediatric and Adult Acute Lymphoblastic Leukemia: A Meta-analysis. JAMA Oncol. 2017 Jul 13; 3(7):e170580. PMID: 28494052; PMCID: PMC5824235.
      Citations: 122     Fields:    Translation:Humans
    50. Huang X, Li Y, Song J, Berry DA. A Bayesian Simulation Model for Breast Cancer Screening, Incidence, Treatment, and Mortality. Med Decis Making. 2018 04; 38(1_suppl):78S-88S. PMID: 28627297; PMCID: PMC5711634.
      Citations: 8     Fields:    Translation:Humans
    51. Berry DA. Adoption of Pathologic Complete Response as a Surrogate End Point in Neoadjuvant Trials in HER2-Positive Breast Cancer Still an Open Question-Reply. JAMA Oncol. 2017 03 01; 3(3):416-417. PMID: 27892985.
      Citations: 1     Fields:    Translation:Humans
    52. Mawocha SC, Fetters MD, Legocki LJ, Guetterman TC, Frederiksen S, Barsan WG, Lewis RJ, Berry DA, Meurer WJ. A conceptual model for the development process of confirmatory adaptive clinical trials within an emergency research network. Clin Trials. 2017 Jun; 14(3):246-254. PMID: 28135827; PMCID: PMC5446276.
      Citations: 5     Fields:    Translation:Humans
    53. Ollila DW, Cirrincione CT, Berry DA, Carey LA, Sikov WM, Hudis CA, Winer EP, Golshan M. Axillary Management of Stage II/III Breast Cancer in Patients Treated with Neoadjuvant Systemic Therapy: Results of CALGB 40601 (HER2-Positive) and CALGB 40603 (Triple-Negative). J Am Coll Surg. 2017 Apr; 224(4):688-694. PMID: 28089784; PMCID: PMC5616181.
      Citations:    Fields:    Translation:Humans
    54. Freedman RA, Seisler DK, Foster JC, Sloan JA, Lafky JM, Kimmick GG, Hurria A, Cohen HJ, Winer EP, Hudis CA, Partridge AH, Carey LA, Jatoi A, Klepin HD, Citron M, Berry DA, Shulman LN, Buzdar AU, Suman VJ, Muss HB. Risk of acute myeloid leukemia and myelodysplastic syndrome among older women receiving anthracycline-based adjuvant chemotherapy for breast cancer on Modern Cooperative Group Trials (Alliance A151511). Breast Cancer Res Treat. 2017 01; 161(2):363-373. PMID: 27866278; PMCID: PMC5226883.
      Citations: 3     Fields:    Translation:Humans
    55. Berry D, Esserman L. Adaptive Randomization of Neratinib in Early Breast Cancer. N Engl J Med. 2016 10 20; 375(16):1592-3. PMID: 27797314.
      Citations: 2     Fields:    Translation:Humans
    56. Golshan M, Cirrincione CT, Sikov WM, Carey LA, Berry DA, Overmoyer B, Henry NL, Somlo G, Port E, Burstein HJ, Hudis C, Winer E, Ollila DW, Alliance for Clinical Trials in Oncology. Impact of neoadjuvant therapy on eligibility for and frequency of breast conservation in stage II-III HER2-positive breast cancer: surgical results of CALGB 40601 (Alliance). Breast Cancer Res Treat. 2016 11; 160(2):297-304. PMID: 27704226; PMCID: PMC5189982.
      Citations: 17     Fields:    Translation:Humans
    57. Meurer WJ, Legocki L, Mawocha S, Frederiksen SM, Guetterman TC, Barsan W, Lewis R, Berry D, Fetters M. Attitudes and opinions regarding confirmatory adaptive clinical trials: a mixed methods analysis from the Adaptive Designs Accelerating Promising Trials into Treatments (ADAPT-IT) project. Trials. 2016 07 29; 17:373. PMID: 27473126; PMCID: PMC4966769.
      Citations: 14     Fields:    Translation:Humans
    58. Park JW, Liu MC, Yee D, Yau C, van 't Veer LJ, Symmans WF, Paoloni M, Perlmutter J, Hylton NM, Hogarth M, DeMichele A, Buxton MB, Chien AJ, Wallace AM, Boughey JC, Haddad TC, Chui SY, Kemmer KA, Kaplan HG, Isaacs C, Nanda R, Tripathy D, Albain KS, Edmiston KK, Elias AD, Northfelt DW, Pusztai L, Moulder SL, Lang JE, Viscusi RK, Euhus DM, Haley BB, Khan QJ, Wood WC, Melisko M, Schwab R, Helsten T, Lyandres J, Davis SE, Hirst GL, Sanil A, Esserman LJ, Berry DA, I-SPY 2 Investigators. Adaptive Randomization of Neratinib in Early Breast Cancer. N Engl J Med. 2016 Jul 07; 375(1):11-22. PMID: 27406346; PMCID: PMC5259558.
      Citations: 117     Fields:    Translation:HumansCTClinical Trials
    59. Rugo HS, Olopade OI, DeMichele A, Yau C, van 't Veer LJ, Buxton MB, Hogarth M, Hylton NM, Paoloni M, Perlmutter J, Symmans WF, Yee D, Chien AJ, Wallace AM, Kaplan HG, Boughey JC, Haddad TC, Albain KS, Liu MC, Isaacs C, Khan QJ, Lang JE, Viscusi RK, Pusztai L, Moulder SL, Chui SY, Kemmer KA, Elias AD, Edmiston KK, Euhus DM, Haley BB, Nanda R, Northfelt DW, Tripathy D, Wood WC, Ewing C, Schwab R, Lyandres J, Davis SE, Hirst GL, Sanil A, Berry DA, Esserman LJ, I-SPY 2 Investigators. Adaptive Randomization of Veliparib-Carboplatin Treatment in Breast Cancer. N Engl J Med. 2016 Jul 07; 375(1):23-34. PMID: 27406347; PMCID: PMC5259561.
      Citations: 177     Fields:    Translation:HumansCTClinical Trials
    60. Broglio KR, Quintana M, Foster M, Olinger M, McGlothlin A, Berry SM, Brezden-Masley C, Chia S, Dent S, Gelmon K, Paterson A, Rayson D, Berry DA, Boileau JF. Association of Pathologic Complete Response to Neoadjuvant Therapy in HER2-Positive Breast Cancer With Long-Term Outcomes: A Meta-Analysis. JAMA Oncol. 2016 Jun 01; 2(6):751-60. PMID: 26914222.
      Citations: 77     Fields:    Translation:Humans
    61. Satlin A, Wang J, Logovinsky V, Berry S, Swanson C, Dhadda S, Berry DA. Design of a Bayesian adaptive phase 2 proof-of-concept trial for?BAN2401, a putative disease-modifying monoclonal antibody for?the?treatment of Alzheimer's disease. Alzheimers Dement (N Y). 2016 Jan; 2(1):1-12. PMID: 29067290; PMCID: PMC5644271.
      Citations: 19     
    62. Mandelblatt JS, Stout NK, Schechter CB, van den Broek JJ, Miglioretti DL, Krapcho M, Trentham-Dietz A, Munoz D, Lee SJ, Berry DA, van Ravesteyn NT, Alagoz O, Kerlikowske K, Tosteson AN, Near AM, Hoeffken A, Chang Y, Heijnsdijk EA, Chisholm G, Huang X, Huang H, Ergun MA, Gangnon R, Sprague BL, Plevritis S, Feuer E, de Koning HJ, Cronin KA. Collaborative Modeling of the Benefits and Harms Associated With Different U.S. Breast Cancer Screening Strategies. Ann Intern Med. 2016 Feb 16; 164(4):215-25. PMID: 26756606; PMCID: PMC5079106.
      Citations: 90     Fields:    Translation:HumansPHPublic Health
    63. DeMichele A, Yee D, Paoloni M, Berry D, Esserman LJ, I-SPY2 Investigators. Neoadjuvant as Future for Drug Development in Breast Cancer--Response. Clin Cancer Res. 2016 Jan 01; 22(1):269. PMID: 26728411.
      Citations: 2     Fields:    Translation:Humans
    64. Berry DA. Emerging innovations in clinical trial design. Clin Pharmacol Ther. 2016 Jan; 99(1):82-91. PMID: 26561040.
      Citations: 12     Fields:    Translation:Humans
    65. Carey LA, Berry DA, Cirrincione CT, Barry WT, Pitcher BN, Harris LN, Ollila DW, Krop IE, Henry NL, Weckstein DJ, Anders CK, Singh B, Hoadley KA, Iglesia M, Cheang MC, Perou CM, Winer EP, Hudis CA. Molecular Heterogeneity and Response to Neoadjuvant Human Epidermal Growth Factor Receptor 2 Targeting in CALGB 40601, a Randomized Phase III Trial of Paclitaxel Plus Trastuzumab With or Without Lapatinib. J Clin Oncol. 2016 Feb 20; 34(6):542-9. PMID: 26527775; PMCID: PMC4980567.
      Citations: 132     Fields:    Translation:HumansCTClinical Trials
    66. Levin VA, Tonge PJ, Gallo JM, Birtwistle MR, Dar AC, Iavarone A, Paddison PJ, Heffron TP, Elmquist WF, Lachowicz JE, Johnson TW, White FM, Sul J, Smith QR, Shen W, Sarkaria JN, Samala R, Wen PY, Berry DA, Petter RC. CNS Anticancer Drug Discovery and Development Conference White Paper. Neuro Oncol. 2015 Nov; 17 Suppl 6:vi1-26. PMID: 26403167; PMCID: PMC4581696.
      Citations: 21     Fields:    Translation:HumansAnimals
    67. Berry DA. Right-Sizing Adjuvant and Neoadjuvant Clinical Trials in Breast Cancer. Clin Cancer Res. 2016 Jan 01; 22(1):3-5. PMID: 26510857; PMCID: PMC4703523.
      Citations: 1     Fields:    Translation:Humans
    68. Bates SE, Berry DA, Balasubramaniam S, Bailey S, LoRusso PM, Rubin EH. Advancing Clinical Trials to Streamline Drug Development. Clin Cancer Res. 2015 Oct 15; 21(20):4527-35. PMID: 26473188; PMCID: PMC6063985.
      Citations: 12     Fields:    Translation:HumansAnimals
    69. Berry DA, Hudis CA. Neoadjuvant Therapy in Breast Cancer as a Basis for Drug Approval. JAMA Oncol. 2015 Oct; 1(7):875-6. PMID: 26181139.
      Citations: 16     Fields:    Translation:Humans
    70. Guetterman TC, Fetters MD, Legocki LJ, Mawocha S, Barsan WG, Lewis RJ, Berry DA, Meurer WJ. Reflections on the Adaptive Designs Accelerating Promising Trials Into Treatments (ADAPT-IT) Process-Findings from a Qualitative Study. Clin Res Regul Aff. 2015 Oct 02; 32(4):121-130. PMID: 26622163; PMCID: PMC4662412.
      Citations: 9     
    71. Cirrincione CT, Sikov WM, Berry DA, Jasinski S, Weisberg TF, Somlo G, Hudis C, Winer E, Ollila DW, Alliance for Clinical Trials in Oncology, Golshan M. Impact of neoadjuvant chemotherapy in stage II-III triple negative breast cancer on eligibility for breast-conserving surgery and breast conservation rates: surgical results from CALGB 40603 (Alliance). Ann Surg. 2015 Sep; 262(3):434-9; discussion 438-9. PMID: 26222764; PMCID: PMC4710511.
      Citations: 56     Fields:    Translation:HumansCTClinical Trials
    72. Raghav KP, Mahajan S, Yao JC, Hobbs BP, Berry DA, Pentz RD, Tam A, Hong WK, Ellis LM, Abbruzzese J, Overman MJ. From Protocols to Publications: A Study in Selective Reporting of Outcomes in Randomized Trials in Oncology. J Clin Oncol. 2015 Nov 01; 33(31):3583-90. PMID: 26304898; PMCID: PMC4979242.
      Citations: 18     Fields:    Translation:Humans
    73. Pritchett YL, Berry SM, Llano DA, Han S, Berry DA, Sadowsky CH, Abi-Saab WM, Saltarelli MD, Lenz RA. Adaptive, dose-finding phase 2 trial evaluating the safety and efficacy of ABT-089 in mild to moderate Alzheimer disease. Alzheimer Dis Assoc Disord. 2015 Jul-Sep; 29(3):192-9. PMID: 25973909.
      Citations: 9     Fields:    Translation:HumansCTClinical Trials
    74. Ligibel JA, Cirrincione CT, Liu M, Citron M, Ingle JN, Gradishar W, Martino S, Sikov W, Michaelson R, Mardis E, Perou CM, Ellis M, Winer E, Hudis CA, Berry D, Barry WT. Body Mass Index, PAM50 Subtype, and Outcomes in Node-Positive Breast Cancer: CALGB 9741 (Alliance). J Natl Cancer Inst. 2015 Sep; 107(9). PMID: 26113580; PMCID: PMC4651106.
      Citations: 27     Fields:    Translation:Humans
    75. Chang JY, Senan S, Paul MA, Mehran RJ, Louie AV, Balter P, Groen HJ, McRae SE, Widder J, Feng L, van den Borne BE, Munsell MF, Hurkmans C, Berry DA, van Werkhoven E, Kresl JJ, Dingemans AM, Dawood O, Haasbeek CJ, Carpenter LS, De Jaeger K, Komaki R, Slotman BJ, Smit EF, Roth JA. Stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small-cell lung cancer: a pooled analysis of two randomised trials. Lancet Oncol. 2015 Jun; 16(6):630-7. PMID: 25981812; PMCID: PMC4489408.
      Citations: 453     Fields:    Translation:HumansCTClinical Trials
    76. Kang BP, Slosberg E, Snodgrass S, Lebedinsky C, Berry DA, Corless CL, Stein S, Salvado A. The Signature Program: Bringing the Protocol to the Patient. Clin Pharmacol Ther. 2015 Aug; 98(2):124-6. PMID: 25810246; PMCID: PMC4676287.
      Citations: 13     Fields:    Translation:Humans
    77. Legocki LJ, Meurer WJ, Frederiksen S, Lewis RJ, Durkalski VL, Berry DA, Barsan WG, Fetters MD. Clinical trialist perspectives on the ethics of adaptive clinical trials: a mixed-methods analysis. BMC Med Ethics. 2015 May 03; 16:27. PMID: 25933921; PMCID: PMC4424427.
      Citations: 15     Fields:    Translation:Humans
    78. Berry DA. The Brave New World of clinical cancer research: Adaptive biomarker-driven trials integrating clinical practice with clinical research. Mol Oncol. 2015 May; 9(5):951-9. PMID: 25888066; PMCID: PMC4516171.
      Citations: 43     Fields:    Translation:Humans
    79. DeMichele A, Yee D, Berry DA, Albain KS, Benz CC, Boughey J, Buxton M, Chia SK, Chien AJ, Chui SY, Clark A, Edmiston K, Elias AD, Forero-Torres A, Haddad TC, Haley B, Haluska P, Hylton NM, Isaacs C, Kaplan H, Korde L, Leyland-Jones B, Liu MC, Melisko M, Minton SE, Moulder SL, Nanda R, Olopade OI, Paoloni M, Park JW, Parker BA, Perlmutter J, Petricoin EF, Rugo H, Symmans F, Tripathy D, van't Veer LJ, Viscusi RK, Wallace A, Wolf D, Yau C, Esserman LJ. The Neoadjuvant Model Is Still the Future for Drug Development in Breast Cancer. Clin Cancer Res. 2015 Jul 01; 21(13):2911-5. PMID: 25712686; PMCID: PMC4490043.
      Citations: 40     Fields:    Translation:Humans
    80. Berry DA. Commentary on Hey and Kimmelman. Clin Trials. 2015 Apr; 12(2):107-9. PMID: 25649111.
      Citations: 8     Fields:    Translation:Humans
    81. Trippa L, Wen PY, Parmigiani G, Berry DA, Alexander BM. Combining progression-free survival and overall survival as a novel composite endpoint for glioblastoma trials. Neuro Oncol. 2015 Aug; 17(8):1106-13. PMID: 25568226; PMCID: PMC4490868.
      Citations: 9     Fields:    Translation:Humans
    82. Shulman LN, Berry DA, Cirrincione CT, Hudis CA, Winer EP. Reply to V. Amoroso et al. J Clin Oncol. 2015 Jan 20; 33(3):291. PMID: 25512457.
      Citations:    Fields:    Translation:Humans
    83. Venook AP, Arcila ME, Benson AB, Berry DA, Camidge DR, Carlson RW, Choueiri TK, Guild V, Kalemkerian GP, Kurzrock R, Lovly CM, McKee AE, Morgan RJ, Olszanski AJ, Redman MW, Stearns V, McClure J, Birkeland ML. NCCN Working Group report: designing clinical trials in the era of multiple biomarkers and targeted therapies. J Natl Compr Canc Netw. 2014 Nov; 12(11):1629-49. PMID: 25361808; PMCID: PMC5241088.
      Citations: 5     Fields:    Translation:Humans
    84. Munoz D, Near AM, van Ravesteyn NT, Lee SJ, Schechter CB, Alagoz O, Berry DA, Burnside ES, Chang Y, Chisholm G, de Koning HJ, Ali Ergun M, Heijnsdijk EA, Huang H, Stout NK, Sprague BL, Trentham-Dietz A, Mandelblatt JS, Plevritis SK. Effects of screening and systemic adjuvant therapy on ER-specific US breast cancer mortality. J Natl Cancer Inst. 2014 Nov; 106(11). PMID: 25255803; PMCID: PMC4271026.
      Citations: 58     Fields:    Translation:HumansPHPublic Health
    85. Alexander BM, Galanis E, Yung WK, Ballman KV, Boyett JM, Cloughesy TF, Degroot JF, Huse JT, Mann B, Mason W, Mellinghoff IK, Mikkelsen T, Mischel PS, O'Neill BP, Prados MD, Sarkaria JN, Tawab-Amiri A, Trippa L, Ye X, Ligon KL, Berry DA, Wen PY. Brain Malignancy Steering Committee clinical trials planning workshop: report from the Targeted Therapies Working Group. Neuro Oncol. 2015 Feb; 17(2):180-8. PMID: 25165194; PMCID: PMC4288520.
      Citations: 11     Fields:    Translation:Humans
    86. Sikov WM, Berry DA, Perou CM, Singh B, Cirrincione CT, Tolaney SM, Kuzma CS, Pluard TJ, Somlo G, Port ER, Golshan M, Bellon JR, Collyar D, Hahn OM, Carey LA, Hudis CA, Winer EP. Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603 (Alliance). J Clin Oncol. 2015 Jan 01; 33(1):13-21. PMID: 25092775; PMCID: PMC4268249.
      Citations: 311     Fields:    Translation:HumansCTClinical Trials
    87. Berry DA. CYP2D6 genotype and adjuvant tamoxifen. Clin Pharmacol Ther. 2014 Aug; 96(2):138-40. PMID: 25056391.
      Citations: 6     Fields:    Translation:Humans
    88. Tsimberidou AM, Wen S, Hong DS, Wheler JJ, Falchook GS, Fu S, Piha-Paul S, Naing A, Janku F, Aldape K, Ye Y, Kurzrock R, Berry D. Personalized medicine for patients with advanced cancer in the phase I program at MD Anderson: validation and landmark analyses. Clin Cancer Res. 2014 Sep 15; 20(18):4827-36. PMID: 24987059; PMCID: PMC4518867.
      Citations: 98     Fields:    Translation:Humans
    89. Shulman LN, Berry DA, Cirrincione CT, Becker HP, Perez EA, O'Regan R, Martino S, Shapiro CL, Schneider CJ, Kimmick G, Burstein HJ, Norton L, Muss H, Hudis CA, Winer EP. Comparison of doxorubicin and cyclophosphamide versus single-agent paclitaxel as adjuvant therapy for breast cancer in women with 0 to 3 positive axillary nodes: CALGB 40101 (Alliance). J Clin Oncol. 2014 Aug 01; 32(22):2311-7. PMID: 24934787; PMCID: PMC4105484.
      Citations: 27     Fields:    Translation:Humans
    90. Berry DA. Failure of researchers, reviewers, editors, and the media to understand flaws in cancer screening studies: application to an article in Cancer. Cancer. 2014 Sep 15; 120(18):2784-91. PMID: 24925345.
      Citations: 8     Fields:    Translation:Humans
    91. Stout NK, Lee SJ, Schechter CB, Kerlikowske K, Alagoz O, Berry D, Buist DS, Cevik M, Chisholm G, de Koning HJ, Huang H, Hubbard RA, Miglioretti DL, Munsell MF, Trentham-Dietz A, van Ravesteyn NT, Tosteson AN, Mandelblatt JS. Benefits, harms, and costs for breast cancer screening after US implementation of digital mammography. J Natl Cancer Inst. 2014 Jun; 106(6):dju092. PMID: 24872543; PMCID: PMC4067109.
      Citations: 54     Fields:    Translation:HumansPHPublic Health
    92. Esserman LJ, Thompson IM, Reid B, Nelson P, Ransohoff DF, Welch HG, Hwang S, Berry DA, Kinzler KW, Black WC, Bissell M, Parnes H, Srivastava S. Addressing overdiagnosis and overtreatment in cancer: a prescription for change. Lancet Oncol. 2014 May; 15(6):e234-42. PMID: 24807866; PMCID: PMC4322920.
      Citations: 151     Fields:    Translation:Humans
    93. Berry DA. Response. J Natl Cancer Inst. 2014 Apr 03; 106(5). PMID: 24700800.
      Citations: 1     Fields:    Translation:Humans
    94. Broglio KR, Stivers DN, Berry DA. Predicting clinical trial results based on announcements of interim analyses. Trials. 2014 Mar 07; 15:73. PMID: 24607270; PMCID: PMC3973959.
      Citations: 3     Fields:    Translation:Humans
    95. Berry DA. Response. J Natl Cancer Inst. 2014 Feb; 106(2):djt380. PMID: 24408654.
      Citations: 1     Fields:    Translation:Humans
    96. Munsell MF, Sprague BL, Berry DA, Chisholm G, Trentham-Dietz A. Body mass index and breast cancer risk according to postmenopausal estrogen-progestin use and hormone receptor status. Epidemiol Rev. 2014; 36:114-36. PMID: 24375928; PMCID: PMC3873844.
      Citations: 139     Fields:    Translation:Humans
    97. Hughes KS, Schnaper LA, Bellon JR, Cirrincione CT, Berry DA, McCormick B, Muss HB, Smith BL, Hudis CA, Winer EP, Wood WC. Reply to P.G. Tsoutsou et al, o. Kaidar-Person et al, and A. Courdi et al. J Clin Oncol. 2013 Dec 20; 31(36):4571-3. PMID: 24190113.
      Citations:    Fields:    Translation:Humans
    98. Campbell MJ, Wolf D, Mukhtar RA, Tandon V, Yau C, Au A, Baehner F, van't Veer L, Berry D, Esserman LJ. The prognostic implications of macrophages expressing proliferating cell nuclear antigen in breast cancer depend on immune context. PLoS One. 2013; 8(10):e79114. PMID: 24205370; PMCID: PMC3812150.
      Citations: 12     Fields:    Translation:HumansCells
    99. Ajani JA, Wang X, Song S, Suzuki A, Taketa T, Sudo K, Wadhwa R, Hofstetter WL, Komaki R, Maru DM, Lee JH, Bhutani MS, Weston B, Baladandayuthapani V, Yao Y, Honjo S, Scott AW, Skinner HD, Johnson RL, Berry D. ALDH-1 expression levels predict response or resistance to preoperative chemoradiation in resectable esophageal cancer patients. Mol Oncol. 2014 Feb; 8(1):142-9. PMID: 24210755; PMCID: PMC3946849.
      Citations: 55     Fields:    Translation:HumansCells
    100. Berry SM, Broglio KR, Groshen S, Berry DA. Bayesian hierarchical modeling of patient subpopulations: efficient designs of Phase II oncology clinical trials. Clin Trials. 2013 Oct; 10(5):720-34. PMID: 23983156; PMCID: PMC4319656.
      Citations: 35     Fields:    Translation:Humans
    101. Berry D. CYP2D6 genotyping and the use of tamoxifen in breast cancer. J Natl Cancer Inst. 2013 Sep 04; 105(17):1267-9. PMID: 23958737.
      Citations: 7     Fields:    Translation:Humans
    102. Berry DA. Breast cancer screening: controversy of impact. Breast. 2013 Aug; 22 Suppl 2:S73-6. PMID: 24074796; PMCID: PMC4192714.
      Citations: 9     Fields:    Translation:HumansPHPublic Health
    103. Wen PY, Trippa L, Reardon DA, Yung WK, Parmigiani G, Berry DA, Alexander BM. Biomarker-based adaptive trials for patients with glioblastoma--lessons from I-SPY 2. Neuro Oncol. 2013 Aug; 15(8):972-8. PMID: 23857706; PMCID: PMC3714161.
      Citations: 14     Fields:    Translation:Humans
    104. Hughes KS, Schnaper LA, Bellon JR, Cirrincione CT, Berry DA, McCormick B, Muss HB, Smith BL, Hudis CA, Winer EP, Wood WC. Lumpectomy plus tamoxifen with or without irradiation in women age 70 years or older with early breast cancer: long-term follow-up of CALGB 9343. J Clin Oncol. 2013 Jul 01; 31(19):2382-7. PMID: 23690420; PMCID: PMC3691356.
      Citations: 287     Fields:    Translation:Humans
    105. Johnson CM, Wei C, Ensor JE, Smolenski DJ, Amos CI, Levin B, Berry DA. Meta-analyses of colorectal cancer risk factors. Cancer Causes Control. 2013 Jun; 24(6):1207-22. PMID: 23563998; PMCID: PMC4161278.
      Citations: 207     Fields:    Translation:Humans
    106. DeMichele A, Berry DA, Zujewski J, Hunsberger S, Rubinstein L, Tomaszewski JE, Kelloff G, Perlmutter J, Buxton M, Lyandres J, Albain KS, Benz C, Chien AJ, Haluska P, Leyland-Jones B, Liu MC, Munster P, Olopade O, Park JW, Parker BA, Pusztai L, Tripathy D, Rugo H, Yee D, Esserman L. Developing safety criteria for introducing new agents into neoadjuvant trials. Clin Cancer Res. 2013 Jun 01; 19(11):2817-23. PMID: 23470967; PMCID: PMC4096560.
      Citations: 7     Fields:    Translation:Humans
    107. Prat A, Ebbert MT, Ruiz-Borrego M, Bastien RR, Crespo C, Davis C, Casas M, Ellis MJ, Berry DA, Pitcher BN, Harris L, Ruiz A, Winer E, Hudis C, Stijleman IJ, Tuck DP, Carrasco E, Perou CM, Bernard PS, Mart?n M, Rodr?guez-Lescure A, Caballero R, Mun?rriz B, Rodr?guez CA, L?pez-Vega JM, Furi? V, Garc?a AM. PAM50 proliferation score as a predictor of weekly paclitaxel benefit in breast cancer. Breast Cancer Res Treat. 2013 Apr; 138(2):457-66. PMID: 23423445; PMCID: PMC3608881.
      Citations: 40     Fields:    Translation:Humans
    108. Yee D, Haddad T, Albain K, Barker A, Benz C, Boughey J, Buxton M, Chien AJ, DeMichele A, Dilts D, Elias A, Haluska P, Hogarth M, Hu A, Hytlon N, Kaplan HG, Kelloff GG, Khan Q, Lang J, Leyland-Jones B, Liu M, Nanda R, Northfelt D, Olopade OI, Park J, Parker B, Parkinson D, Pearson-White S, Perlmutter J, Pusztai L, Symmans F, Rugo H, Tripathy D, Wallace A, Wholley D, Van't Veer L, Berry DA, Esserman L. Adaptive trials in the neoadjuvant setting: a model to safely tailor care while accelerating drug development. J Clin Oncol. 2012 Dec 20; 30(36):4584-6; author reply 4588-9. PMID: 23169510.
      Citations: 4     Fields:    Translation:Humans
    109. Janku F, Berry DA, Gong J, Parsons HA, Stewart DJ, Kurzrock R. Outcomes of phase II clinical trials with single-agent therapies in advanced/metastatic non-small cell lung cancer published between 2000 and 2009. Clin Cancer Res. 2012 Nov 15; 18(22):6356-63. PMID: 23014530.
      Citations: 13     Fields:    Translation:Humans
    110. Younes A, Berry DA. From drug discovery to biomarker-driven clinical trials in lymphoma. Nat Rev Clin Oncol. 2012 Nov; 9(11):643-53. PMID: 22965151; PMCID: PMC5206990.
      Citations: 13     Fields:    Translation:Humans
    111. Tsimberidou AM, Iskander NG, Hong DS, Wheler JJ, Falchook GS, Fu S, Piha-Paul S, Naing A, Janku F, Luthra R, Ye Y, Wen S, Berry D, Kurzrock R. Personalized medicine in a phase I clinical trials program: the MD Anderson Cancer Center initiative. Clin Cancer Res. 2012 Nov 15; 18(22):6373-83. PMID: 22966018; PMCID: PMC4454458.
      Citations: 245     Fields:    Translation:Humans
    112. Lips EH, Mukhtar RA, Yau C, de Ronde JJ, Livasy C, Carey LA, Loo CE, Vrancken-Peeters MJ, Sonke GS, Berry DA, Van't Veer LJ, Esserman LJ, Wesseling J, Rodenhuis S, Shelley Hwang E, I-SPY TRIAL Investigators. Lobular histology and response to neoadjuvant chemotherapy in invasive breast cancer. Breast Cancer Res Treat. 2012 Nov; 136(1):35-43. PMID: 22961065; PMCID: PMC5702179.
      Citations: 31     Fields:    Translation:Humans
    113. Berry D. Multiplicities in cancer research: ubiquitous and necessary evils. J Natl Cancer Inst. 2012 Aug 08; 104(15):1124-32. PMID: 22859849; PMCID: PMC4614276.
      Citations: 10     Fields:    Translation:Humans
    114. Shulman LN, Cirrincione CT, Berry DA, Becker HP, Perez EA, O'Regan R, Martino S, Atkins JN, Mayer E, Schneider CJ, Kimmick G, Norton L, Muss H, Winer EP, Hudis C. Six cycles of doxorubicin and cyclophosphamide or Paclitaxel are not superior to four cycles as adjuvant chemotherapy for breast cancer in women with zero to three positive axillary nodes: Cancer and Leukemia Group B 40101. J Clin Oncol. 2012 Nov 20; 30(33):4071-6. PMID: 22826271; PMCID: PMC3494835.
      Citations: 35     Fields:    Translation:HumansCTClinical Trials
    115. Collins SP, Lindsell CJ, Pang PS, Storrow AB, Peacock WF, Levy P, Rahbar MH, Del Junco D, Gheorghiade M, Berry DA. Bayesian adaptive trial design in acute heart failure syndromes: moving beyond the mega trial. Am Heart J. 2012 Aug; 164(2):138-45. PMID: 22877798; PMCID: PMC3417230.
      Citations: 14     Fields:    Translation:Humans
    116. O'Brien S, Rizzieri DA, Vey N, Ravandi F, Krug UO, Sekeres MA, Dennis M, Venditti A, Berry DA, Jacobsen TF, Staudacher K, Bergeland T, Giles FJ. Elacytarabine has single-agent activity in patients with advanced acute myeloid leukaemia. Br J Haematol. 2012 Sep; 158(5):581-8. PMID: 22702906; PMCID: PMC4191720.
      Citations: 9     Fields:    Translation:HumansCTClinical Trials
    117. Meurer WJ, Lewis RJ, Berry DA. Adaptive clinical trials: a partial remedy for the therapeutic misconception? JAMA. 2012 Jun 13; 307(22):2377-8. PMID: 22692168.
      Citations: 32     Fields:    Translation:Humans
    118. Bach PB, Mirkin JN, Oliver TK, Azzoli CG, Berry DA, Brawley OW, Byers T, Colditz GA, Gould MK, Jett JR, Sabichi AL, Smith-Bindman R, Wood DE, Qaseem A, Detterbeck FC. Benefits and harms of CT screening for lung cancer: a systematic review. JAMA. 2012 Jun 13; 307(22):2418-29. PMID: 22610500; PMCID: PMC3709596.
      Citations: 402     Fields:    Translation:Humans
    119. Esserman LJ, Berry DA, DeMichele A, Carey L, Davis SE, Buxton M, Hudis C, Gray JW, Perou C, Yau C, Livasy C, Krontiras H, Montgomery L, Tripathy D, Lehman C, Liu MC, Olopade OI, Rugo HS, Carpenter JT, Dressler L, Chhieng D, Singh B, Mies C, Rabban J, Chen YY, Giri D, van 't Veer L, Hylton N. Pathologic complete response predicts recurrence-free survival more effectively by cancer subset: results from the I-SPY 1 TRIAL--CALGB 150007/150012, ACRIN 6657. J Clin Oncol. 2012 Sep 10; 30(26):3242-9. PMID: 22649152; PMCID: PMC3434983.
      Citations: 173     Fields:    Translation:Humans
    120. Meurer WJ, Lewis RJ, Tagle D, Fetters MD, Legocki L, Berry S, Connor J, Durkalski V, Elm J, Zhao W, Frederiksen S, Silbergleit R, Palesch Y, Berry DA, Barsan WG. An overview of the adaptive designs accelerating promising trials into treatments (ADAPT-IT) project. Ann Emerg Med. 2012 Oct; 60(4):451-7. PMID: 22424650; PMCID: PMC3557826.
      Citations: 24     Fields:    Translation:Humans
    121. Berry DA, Herbst RS, Rubin EH. Reports from the 2010 Clinical and Translational Cancer Research Think Tank meeting: design strategies for personalized therapy trials. Clin Cancer Res. 2012 Feb 01; 18(3):638-44. PMID: 22298897; PMCID: PMC4314693.
      Citations: 18     Fields:    Translation:Humans
    122. Ellenberg S, Luce B, Fleming T, Siegel J, Strom B, Temple R, Sackett D, Bourguignon C, Bekelman J, Berry D, Rotelli M, Judkins D, Schwartz S, Goodman S, Hern?n M. Panel discussion 2. Clin Trials. 2012 Feb; 9(1):66-79. PMID: 22334467.
      Citations:    Fields:    
    123. Ji Y, Feng L, Liu P, Shpall EJ, Kebriaei P, Champlin R, Berry D, Cooper LJ. Bayesian continual reassessment method for dose-finding trials infusing T cells with limited sample size. J Biopharm Stat. 2012; 22(6):1206-19. PMID: 23075018; PMCID: PMC3501341.
      Citations: 2     Fields:    Translation:HumansCells
    124. Esserman LJ, Berry DA, Cheang MC, Yau C, Perou CM, Carey L, DeMichele A, Gray JW, Conway-Dorsey K, Lenburg ME, Buxton MB, Davis SE, van't Veer LJ, Hudis C, Chin K, Wolf D, Krontiras H, Montgomery L, Tripathy D, Lehman C, Liu MC, Olopade OI, Rugo HS, Carpenter JT, Livasy C, Dressler L, Chhieng D, Singh B, Mies C, Rabban J, Chen YY, Giri D, Au A, Hylton N, I-SPY 1 TRIAL Investigators. Chemotherapy response and recurrence-free survival in neoadjuvant breast cancer depends on biomarker profiles: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657). Breast Cancer Res Treat. 2012 Apr; 132(3):1049-62. PMID: 22198468; PMCID: PMC3332388.
      Citations: 169     Fields:    Translation:Humans
    125. Berry DA. Adaptive clinical trials in oncology. Nat Rev Clin Oncol. 2011 Nov 08; 9(4):199-207. PMID: 22064459.
      Citations: 78     Fields:    Translation:Humans
    126. Mandelblatt JS, Cronin KA, Berry DA, Chang Y, de Koning HJ, Lee SJ, Plevritis SK, Schechter CB, Stout NK, van Ravesteyn NT, Zelen M, Feuer EJ. Modeling the impact of population screening on breast cancer mortality in the United States. Breast. 2011 Oct; 20 Suppl 3:S75-81. PMID: 22015298; PMCID: PMC3457919.
      Citations: 7     Fields:    Translation:HumansPHPublic Health
    127. Berry DA. Bayesian approaches for comparative effectiveness research. Clin Trials. 2012 Feb; 9(1):37-47. PMID: 21878446; PMCID: PMC4314707.
      Citations: 4     Fields:    
    128. Berry DA. Next generation clinical trials. Clin Adv Hematol Oncol. 2011 Aug; 9(8):601-3. PMID: 22236987.
      Citations: 1     Fields:    Translation:Humans
    129. Lin C, Buxton MB, Moore D, Krontiras H, Carey L, DeMichele A, Montgomery L, Tripathy D, Lehman C, Liu M, Olapade O, Yau C, Berry D, Esserman LJ, I-SPY TRIAL Investigators. Locally advanced breast cancers are more likely to present as Interval Cancers: results from the I-SPY 1 TRIAL (CALGB 150007/150012, ACRIN 6657, InterSPORE Trial). Breast Cancer Res Treat. 2012 Apr; 132(3):871-9. PMID: 21796368; PMCID: PMC3975048.
      Citations: 10     Fields:    Translation:Humans
    130. Berry DA. Computer-assisted detection and screening mammography: where's the beef? J Natl Cancer Inst. 2011 Aug 03; 103(15):1139-41. PMID: 21795666.
      Citations: 1     Fields:    Translation:Humans
    131. Berry DA, Ueno NT, Johnson MM, Lei X, Caputo J, Smith DA, Yancey LJ, Crump M, Stadtmauer EA, Biron P, Crown JP, Schmid P, Lotz JP, Rosti G, Bregni M, Demirer T. High-dose chemotherapy with autologous hematopoietic stem-cell transplantation in metastatic breast cancer: overview of six randomized trials. J Clin Oncol. 2011 Aug 20; 29(24):3224-31. PMID: 21768454; PMCID: PMC4322116.
      Citations: 27     Fields:    Translation:Humans
    132. Berry DA, Ueno NT, Johnson MM, Lei X, Caputo J, Rodenhuis S, Peters WP, Leonard RC, Barlow WE, Tallman MS, Bergh J, Nitz UA, Gianni AM, Basser RL, Zander AR, Coombes RC, Tokuda Y, de Vries EG, Hortobagyi GN, Crown JP, Pedrazzoli P, Bregni M, Demirer T, Roch? H. High-dose chemotherapy with autologous stem-cell support as adjuvant therapy in breast cancer: overview of 15 randomized trials. J Clin Oncol. 2011 Aug 20; 29(24):3214-23. PMID: 21768471; PMCID: PMC4322115.
      Citations: 32     Fields:    Translation:Humans
    133. Lara JF, Thor AD, Dressler LG, Broadwater G, Bleiweiss IJ, Edgerton S, Cowan D, Goldstein LJ, Martino S, Ingle JN, Henderson IC, Norton L, Winer EP, Hudis CA, Ellis MJ, Berry DA, Hayes DF, Cancer and Leukemia Group B. p53 Expression in node-positive breast cancer patients: results from the Cancer and Leukemia Group B 9344 Trial (159905). Clin Cancer Res. 2011 Aug 01; 17(15):5170-8. PMID: 21693655; PMCID: PMC3149770.
      Citations: 19     Fields:    Translation:Humans
    134. Connor JT, Lewis RJ, Berry DA, Berry SM. FDA recalls not as alarming as they seem. Arch Intern Med. 2011 Jun 13; 171(11):1044-5; author reply 1045-6. PMID: 21670380.
      Citations: 1     Fields:    Translation:HumansPHPublic Health
    135. Schuster SJ, Neelapu SS, Gause BL, Janik JE, Muggia FM, Gockerman JP, Winter JN, Flowers CR, Nikcevich DA, Sotomayor EM, McGaughey DS, Jaffe ES, Chong EA, Reynolds CW, Berry DA, Santos CF, Popa MA, McCord AM, Kwak LW. Vaccination with patient-specific tumor-derived antigen in first remission improves disease-free survival in follicular lymphoma. J Clin Oncol. 2011 Jul 10; 29(20):2787-94. PMID: 21632504; PMCID: PMC3139394.
      Citations: 112     Fields:    Translation:HumansCellsCTClinical Trials
    136. Berry SM, Broglio KR, Berry DA. Addressing the incremental benefit of histamine dihydrochloride when added to interleukin-2 in treating acute myeloid leukemia: a Bayesian meta-analysis. Cancer Invest. 2011 May; 29(4):293-9. PMID: 21469978.
      Citations: 13     Fields:    Translation:Humans
    137. Rimm DL, Nielsen TO, Jewell SD, Rohrer DC, Broadwater G, Waldman F, Mitchell KA, Singh B, Tsongalis GJ, Frankel WL, Magliocco AM, Lara JF, Hsi ED, Bleiweiss IJ, Badve SS, Chen B, Ravdin PM, Schilsky RL, Thor A, Berry DA, Cancer and Leukemia Group B Pathology Committee. Cancer and Leukemia Group B Pathology Committee guidelines for tissue microarray construction representing multicenter prospective clinical trial tissues. J Clin Oncol. 2011 Jun 01; 29(16):2282-90. PMID: 21519016; PMCID: PMC3107745.
      Citations: 15     Fields:    Translation:Humans
    138. Berry DA. Adaptive clinical trials: the promise and the caution. J Clin Oncol. 2011 Feb 20; 29(6):606-9. PMID: 21172875.
      Citations: 59     Fields:    Translation:Humans
    139. Parmar S, Andersson BS, Couriel D, Munsell MF, Fernandez-Vina M, Jones RB, Shpall EJ, Popat U, Anderlini P, Giralt S, Alousi A, Cano P, Bosque D, Hosing C, Silva Lde P, Westmoreland M, Wathen JK, Berry D, Champlin RE, de Lima MJ. Prophylaxis of graft-versus-host disease in unrelated donor transplantation with pentostatin, tacrolimus, and mini-methotrexate: a phase I/II controlled, adaptively randomized study. J Clin Oncol. 2011 Jan 20; 29(3):294-302. PMID: 21149654; PMCID: PMC3056464.
      Citations: 12     Fields:    Translation:HumansCTClinical Trials
    140. Baum M, Thornton H, Bewley S, Barratt A, Ross N, Woloshin S, Schwartz L, Musiello T, Blennerhassett M, Napoli M, Baines CJ, Vaidya JS, Williams N, Havercroft D, Zahl PH, Retsky M, Kaplan RM, Dixon-Woods M, Berry DA, Isaacson K, Brahams D, Pryke M, Tindall G, Bender DA, Marshall T, G?tzsche PC, J?rgensen KJ. Breast cancer awareness month. Still awaiting screening facts. BMJ. 2010 Nov 02; 341:c6152. PMID: 21045038.
      Citations: 5     Fields:    Translation:Humans
    141. Berry DA. The hazards of endpoints. J Natl Cancer Inst. 2010 Sep 22; 102(18):1376-7. PMID: 20826734.
      Citations: 5     Fields:    Translation:Humans
    142. Goodman S, Berry D, Wittes J. Bias and trials stopped early for benefit. JAMA. 2010 Jul 14; 304(2):157; author reply 158-9. PMID: 20628126.
      Citations: 7     Fields:    
    143. Berry SM, Ishak KJ, Luce BR, Berry DA. Bayesian meta-analyses for comparative effectiveness and informing coverage decisions. Med Care. 2010 Jun; 48(6 Suppl):S137-44. PMID: 20473185.
      Citations: 4     Fields:    Translation:Humans
    144. Partridge AH, Archer L, Kornblith AB, Gralow J, Grenier D, Perez E, Wolff AC, Wang X, Kastrissios H, Berry D, Hudis C, Winer E, Muss H. Adherence and persistence with oral adjuvant chemotherapy in older women with early-stage breast cancer in CALGB 49907: adherence companion study 60104. J Clin Oncol. 2010 May 10; 28(14):2418-22. PMID: 20368559; PMCID: PMC2881723.
      Citations: 44     Fields:    Translation:Humans
    145. Berry SM, Spinelli W, Littman GS, Liang JZ, Fardipour P, Berry DA, Lewis RJ, Krams M. A Bayesian dose-finding trial with adaptive dose expansion to flexibly assess efficacy and safety of an investigational drug. Clin Trials. 2010 Apr; 7(2):121-35. PMID: 20338905.
      Citations: 14     Fields:    Translation:Humans
    146. Seymour L, Ivy SP, Sargent D, Spriggs D, Baker L, Rubinstein L, Ratain MJ, Le Blanc M, Stewart D, Crowley J, Groshen S, Humphrey JS, West P, Berry D. The design of phase II clinical trials testing cancer therapeutics: consensus recommendations from the clinical trial design task force of the national cancer institute investigational drug steering committee. Clin Cancer Res. 2010 Mar 15; 16(6):1764-9. PMID: 20215557; PMCID: PMC2840069.
      Citations: 61     Fields:    Translation:Humans
    147. Wilber DJ, Pappone C, Neuzil P, De Paola A, Marchlinski F, Natale A, Macle L, Daoud EG, Calkins H, Hall B, Reddy V, Augello G, Reynolds MR, Vinekar C, Liu CY, Berry SM, Berry DA, ThermoCool AF Trial Investigators. Comparison of antiarrhythmic drug therapy and radiofrequency catheter ablation in patients with paroxysmal atrial fibrillation: a randomized controlled trial. JAMA. 2010 Jan 27; 303(4):333-40. PMID: 20103757.
      Citations: 303     Fields:    Translation:Humans
    148. Hamaoka T, Costelloe CM, Madewell JE, Liu P, Berry DA, Islam R, Theriault RL, Hortobagyi GN, Ueno NT. Tumour response interpretation with new tumour response criteria vs the World Health Organisation criteria in patients with bone-only metastatic breast cancer. Br J Cancer. 2010 Feb 16; 102(4):651-7. PMID: 20104228; PMCID: PMC2837571.
      Citations: 29     Fields:    Translation:Humans
    149. Borthakur G, Huang X, Kantarjian H, Faderl S, Ravandi F, Ferrajoli A, Torma R, Morris G, Berry D, Issa JP. Report of a phase 1/2 study of a combination of azacitidine and cytarabine in acute myelogenous leukemia and high-risk myelodysplastic syndromes. Leuk Lymphoma. 2010 Jan; 51(1):73-8. PMID: 20017599; PMCID: PMC2876330.
      Citations: 14     Fields:    Translation:HumansCTClinical Trials
    150. Shen L, Kantarjian H, Guo Y, Lin E, Shan J, Huang X, Berry D, Ahmed S, Zhu W, Pierce S, Kondo Y, Oki Y, Jelinek J, Saba H, Estey E, Issa JP. DNA methylation predicts survival and response to therapy in patients with myelodysplastic syndromes. J Clin Oncol. 2010 Feb 01; 28(4):605-13. PMID: 20038729; PMCID: PMC2815995.
      Citations: 121     Fields:    Translation:HumansCells
    151. Mandelblatt JS, Cronin KA, Bailey S, Berry DA, de Koning HJ, Draisma G, Huang H, Lee SJ, Munsell M, Plevritis SK, Ravdin P, Schechter CB, Sigal B, Stoto MA, Stout NK, van Ravesteyn NT, Venier J, Zelen M, Feuer EJ, Breast Cancer Working Group of the Cancer Intervention and Surveillance Modeling Network. Effects of mammography screening under different screening schedules: model estimates of potential benefits and harms. Ann Intern Med. 2009 Nov 17; 151(10):738-47. PMID: 19920274; PMCID: PMC3515682.
      Citations: 187     Fields:    Translation:HumansPHPublic Health
    152. Broglio KR, Berry DA. Detecting an overall survival benefit that is derived from progression-free survival. J Natl Cancer Inst. 2009 Dec 02; 101(23):1642-9. PMID: 19903805; PMCID: PMC4137232.
      Citations: 183     Fields:    Translation:Humans
    153. Gonzalez-Angulo AM, Litton JK, Broglio KR, Meric-Bernstam F, Rakkhit R, Cardoso F, Peintinger F, Hanrahan EO, Sahin A, Guray M, Larsimont D, Feoli F, Stranzl H, Buchholz TA, Valero V, Theriault R, Piccart-Gebhart M, Ravdin PM, Berry DA, Hortobagyi GN. High risk of recurrence for patients with breast cancer who have human epidermal growth factor receptor 2-positive, node-negative tumors 1 cm or smaller. J Clin Oncol. 2009 Dec 01; 27(34):5700-6. PMID: 19884543; PMCID: PMC2792998.
      Citations: 138     Fields:    Translation:Humans
    154. Allred DC, Carlson RW, Berry DA, Burstein HJ, Edge SB, Goldstein LJ, Gown A, Hammond ME, Iglehart JD, Moench S, Pierce LJ, Ravdin P, Schnitt SJ, Wolff AC. NCCN Task Force Report: Estrogen Receptor and Progesterone Receptor Testing in Breast Cancer by Immunohistochemistry. J Natl Compr Canc Netw. 2009 Sep; 7 Suppl 6:S1-S21; quiz S22-3. PMID: 19755043.
      Citations: 44     Fields:    Translation:Humans
    155. Berry DA. Adjuvant chemotherapy for breast cancer in older women. Womens Health (Lond). 2009 Sep; 5(5):453-7. PMID: 19702442.
      Citations:    Fields:    Translation:Humans
    156. Biswas S, Liu DD, Lee JJ, Berry DA. Bayesian clinical trials at the University of Texas M. D. Anderson Cancer Center. Clin Trials. 2009 Jun; 6(3):205-16. PMID: 19528130; PMCID: PMC2913209.
      Citations: 32     Fields:    Translation:Humans
    157. Huang X, Ning J, Li Y, Estey E, Issa JP, Berry DA. Using short-term response information to facilitate adaptive randomization for survival clinical trials. Stat Med. 2009 May 30; 28(12):1680-9. PMID: 19326367; PMCID: PMC2883264.
      Citations: 13     Fields:    Translation:Humans
    158. Harris LN, Broadwater G, Abu-Khalaf M, Cowan D, Thor AD, Budman D, Cirrincione CT, Berry DA, Winer EP, Hudis CA, Hayes DF, Friedman P, Ellis M, Dressler L. Topoisomerase II{alpha} amplification does not predict benefit from dose-intense cyclophosphamide, doxorubicin, and fluorouracil therapy in HER2-amplified early breast cancer: results of CALGB 8541/150013. J Clin Oncol. 2009 Jul 20; 27(21):3430-6. PMID: 19470942; PMCID: PMC4979079.
      Citations: 22     Fields:    Translation:Humans
    159. Muss HB, Berry DA, Cirrincione CT, Theodoulou M, Mauer AM, Kornblith AB, Partridge AH, Dressler LG, Cohen HJ, Becker HP, Kartcheske PA, Wheeler JD, Perez EA, Wolff AC, Gralow JR, Burstein HJ, Mahmood AA, Magrinat G, Magrinat G, Parker BA, Hart RD, Grenier D, Norton L, Hudis CA, Winer EP, CALGB Investigators. Adjuvant chemotherapy in older women with early-stage breast cancer. N Engl J Med. 2009 May 14; 360(20):2055-65. PMID: 19439741; PMCID: PMC3082436.
      Citations: 180     Fields:    Translation:Humans
    160. Barker AD, Sigman CC, Kelloff GJ, Hylton NM, Berry DA, Esserman LJ. I-SPY 2: an adaptive breast cancer trial design in the setting of neoadjuvant chemotherapy. Clin Pharmacol Ther. 2009 Jul; 86(1):97-100. PMID: 19440188.
      Citations: 226     Fields:    Translation:Humans
    161. Berry D, Wathen JK, Newell M. Bayesian model averaging in meta-analysis: vitamin E supplementation and mortality. Clin Trials. 2009 Feb; 6(1):28-41. PMID: 19254931.
      Citations: 23     Fields:    Translation:Humans
    162. Berry DA, Baines CJ, Baum M, Dickersin K, Fletcher SW, Junod B, Maehlen J, Schwartz LM, Welch HG, Woloshin S, Thornton H, Zahl PH, G?tzsche PC, J?rgensen KJ. Flawed inferences about screening mammography's benefit based on observational data. J Clin Oncol. 2009 Feb 01; 27(4):639-40; author reply 641-2. PMID: 19075270.
      Citations: 15     Fields:    Translation:Humans
    163. Berry DA. The science of doping. Nature. 2008 Aug 07; 454(7205):692-3. PMID: 18685682.
      Citations: 6     Fields:    Translation:HumansPHPublic Health
    164. Julian TB, Blumencranz P, Deck K, Whitworth P, Berry DA, Berry SM, Rosenberg A, Chagpar AB, Reintgen D, Beitsch P, Simmons R, Saha S, Mamounas EP, Giuliano A. Novel intraoperative molecular test for sentinel lymph node metastases in patients with early-stage breast cancer. J Clin Oncol. 2008 Jul 10; 26(20):3338-45. PMID: 18612150.
      Citations: 21     Fields:    Translation:Humans
    165. Polite BN, Cirrincione C, Fleming GF, Berry DA, Seidman A, Muss H, Norton L, Shapiro C, Bakri K, Marcom K, Lake D, Schwartz JH, Hudis C, Winer EP. Racial differences in clinical outcomes from metastatic breast cancer: a pooled analysis of CALGB 9342 and 9840--Cancer and Leukemia Group B. J Clin Oncol. 2008 Jun 01; 26(16):2659-65. PMID: 18509177; PMCID: PMC4830463.
      Citations: 11     Fields:    Translation:Humans
    166. Berry DA. The screening mammography paradox: better when found, perhaps better not to find. Br J Cancer. 2008 Jun 03; 98(11):1729-30. PMID: 18506172; PMCID: PMC2410106.
      Citations: 6     Fields:    Translation:Humans
    167. Dong W, Berry DA, Bevers TB, Kau SW, Hsu L, Theriault RL, Shen Y. Prognostic role of detection method and its relationship with tumor biomarkers in breast cancer: the university of Texas M.D. Anderson Cancer Center experience. Cancer Epidemiol Biomarkers Prev. 2008 May; 17(5):1096-103. PMID: 18483331; PMCID: PMC2701362.
      Citations: 12     Fields:    Translation:Humans
    168. DiGiovanna MP, Stern DF, Edgerton S, Broadwater G, Dressler LG, Budman DR, Henderson IC, Norton L, Liu ET, Muss HB, Berry DA, Hayes DF, Thor AD. Influence of activation state of ErbB-2 (HER-2) on response to adjuvant cyclophosphamide, doxorubicin, and fluorouracil for stage II, node-positive breast cancer: study 8541 from the Cancer and Leukemia Group B. J Clin Oncol. 2008 May 10; 26(14):2364-72. PMID: 18390970; PMCID: PMC6589994.
      Citations: 3     Fields:    Translation:HumansCells
    169. Seidman AD, Berry D, Cirrincione C, Harris L, Muss H, Marcom PK, Gipson G, Burstein H, Lake D, Shapiro CL, Ungaro P, Norton L, Winer E, Hudis C. Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: final results of Cancer and Leukemia Group B protocol 9840. J Clin Oncol. 2008 Apr 01; 26(10):1642-9. PMID: 18375893.
      Citations: 190     Fields:    Translation:HumansCTClinical Trials
    170. Kimmick GG, Cirrincione C, Duggan DB, Bhalla K, Robert N, Berry D, Norton L, Lemke S, Henderson IC, Hudis C, Winer E, Cancer and Leukemia Group B. Fifteen-year median follow-up results after neoadjuvant doxorubicin, followed by mastectomy, followed by adjuvant cyclophosphamide, methotrexate, and fluorouracil (CMF) followed by radiation for stage III breast cancer: a phase II trial (CALGB 8944). Breast Cancer Res Treat. 2009 Feb; 113(3):479-90. PMID: 18306034; PMCID: PMC4217205.
      Citations: 3     Fields:    Translation:HumansCTClinical Trials
    171. Wolff AC, Berry D, Carey LA, Colleoni M, Dowsett M, Ellis M, Garber JE, Mankoff D, Paik S, Pusztai L, Smith ML, Zujewski J. Research issues affecting preoperative systemic therapy for operable breast cancer. J Clin Oncol. 2008 Feb 10; 26(5):806-13. PMID: 18258990.
      Citations: 25     Fields:    Translation:Humans
    172. Liu MC, Demetri GD, Berry DA, Norton L, Broadwater G, Robert NJ, Duggan D, Hayes DF, Henderson IC, Lyss A, Hopkins J, Kaufman PA, Marcom PK, Younger J, Lin N, Tkaczuk K, Winer EP, Hudis CA, Cancer and Leukemia Group B. Dose-escalation of filgrastim does not improve efficacy: clinical tolerability and long-term follow-up on CALGB study 9141 adjuvant chemotherapy for node-positive breast cancer patients using dose-intensified doxorubicin plus cyclophosphamide followed by paclitaxel. Cancer Treat Rev. 2008 May; 34(3):223-30. PMID: 18234424; PMCID: PMC2651678.
      Citations: 5     Fields:    Translation:HumansCTClinical Trials
    173. Iversen ES, Katki HA, Chen S, Berry DA, Parmigiani G. Limited family structure and breast cancer risk. JAMA. 2007 Nov 07; 298(17):2007; author reply 2007-8. PMID: 17986693.
      Citations:    Fields:    Translation:Humans
    174. Ratain MJ, Humphrey RW, Gordon GB, Fyfe G, Adamson PC, Fleming TR, Stadler WM, Berry DA, Peck CC. Recommended changes to oncology clinical trial design: revolution or evolution? Eur J Cancer. 2008 Jan; 44(1):8-11. PMID: 17981025; PMCID: PMC2673461.
      Citations: 11     Fields:    Translation:Humans
    175. Hayes DF, Thor AD, Dressler LG, Weaver D, Edgerton S, Cowan D, Broadwater G, Goldstein LJ, Martino S, Ingle JN, Henderson IC, Norton L, Winer EP, Hudis CA, Ellis MJ, Berry DA, Cancer and Leukemia Group B (CALGB) Investigators. HER2 and response to paclitaxel in node-positive breast cancer. N Engl J Med. 2007 Oct 11; 357(15):1496-506. PMID: 17928597.
      Citations: 191     Fields:    Translation:Humans
    176. Johnson CM, Ensor J, Broglio K, Smolenski D, Ravdin P, Amos C, Meric-Bernstam F, Brewster A, Bevers T, Arun B, Berry D. Building a predictive breast cancer risk model. AMIA Annu Symp Proc. 2007 Oct 11; 995. PMID: 18694095.
      Citations:    Fields:    Translation:Humans
    177. Parmigiani G, Chen S, Iversen ES, Friebel TM, Finkelstein DM, Anton-Culver H, Ziogas A, Weber BL, Eisen A, Malone KE, Daling JR, Hsu L, Ostrander EA, Peterson LE, Schildkraut JM, Isaacs C, Corio C, Leondaridis L, Tomlinson G, Amos CI, Strong LC, Berry DA, Weitzel JN, Sand S, Dutson D, Kerber R, Peshkin BN, Euhus DM. Validity of models for predicting BRCA1 and BRCA2 mutations. Ann Intern Med. 2007 Oct 02; 147(7):441-50. PMID: 17909205; PMCID: PMC2423214.
      Citations: 38     Fields:    Translation:Humans
    178. Muss HB, Berry DA, Cirrincione C, Budman DR, Henderson IC, Citron ML, Norton L, Winer EP, Hudis CA, Cancer and Leukemia Group B Experience. Toxicity of older and younger patients treated with adjuvant chemotherapy for node-positive breast cancer: the Cancer and Leukemia Group B Experience. J Clin Oncol. 2007 Aug 20; 25(24):3699-704. PMID: 17704418.
      Citations: 90     Fields:    Translation:Humans
    179. Berry DA, Ravdin PM. Breast cancer trends: a marriage between clinical trial evidence and epidemiology. J Natl Cancer Inst. 2007 Aug 01; 99(15):1139-41. PMID: 17652274.
      Citations: 4     Fields:    Translation:HumansPHPublic Health
    180. Berry DA. The difficult and ubiquitous problems of multiplicities. Pharm Stat. 2007 Jul-Sep; 6(3):155-60. PMID: 17879328.
      Citations: 8     Fields:    Translation:Humans
    181. Berry DA. Adaptive trial design. Clin Adv Hematol Oncol. 2007 Jul; 5(7):522-4. PMID: 17679925.
      Citations: 7     Fields:    Translation:Humans
    182. Huang X, Biswas S, Oki Y, Issa JP, Berry DA. A parallel phase I/II clinical trial design for combination therapies. Biometrics. 2007 Jun; 63(2):429-36. PMID: 17688495.
      Citations: 35     Fields:    Translation:Humans
    183. Berry D. Commentary: the hazards of survival comparisons. Oncologist. 2007 May; 12(5):510-1. PMID: 17522236.
      Citations: 1     Fields:    Translation:Humans
    184. Pujol JL, Paul S, Chouaki N, Peterson P, Moore P, Berry DA, Salzberg M. Survival without common toxicity criteria grade 3/4 toxicity for pemetrexed compared with docetaxel in previously treated patients with advanced non-small cell lung cancer (NSCLC): a risk-benefit analysis. J Thorac Oncol. 2007 May; 2(5):397-401. PMID: 17473654.
      Citations: 14     Fields:    Translation:HumansCTClinical Trials
    185. Ravdin PM, Cronin KA, Howlader N, Berg CD, Chlebowski RT, Feuer EJ, Edwards BK, Berry DA. The decrease in breast-cancer incidence in 2003 in the United States. N Engl J Med. 2007 Apr 19; 356(16):1670-4. PMID: 17442911.
      Citations: 248     Fields:    Translation:Humans
    186. Berry DA. Biomarker studies and other difficult inferential problems: statistical caveats. Semin Oncol. 2007 Apr; 34(2 Suppl 3):S17-22. PMID: 17512432.
      Citations: 3     Fields:    Translation:Humans
    187. Lewis RJ, Lipsky AM, Berry DA. Bayesian decision-theoretic group sequential clinical trial design based on a quadratic loss function: a frequentist evaluation. Clin Trials. 2007; 4(1):5-14. PMID: 17327241.
      Citations: 11     Fields:    Translation:Humans
    188. Rouzier R, Pusztai L, Garbay JR, Delaloge S, Hunt KK, Hortobagyi GN, Berry D, Kuerer HM. Development and validation of nomograms for predicting residual tumor size and the probability of successful conservative surgery with neoadjuvant chemotherapy for breast cancer. Cancer. 2006 Oct 01; 107(7):1459-66. PMID: 16948128.
      Citations: 12     Fields:    Translation:Humans
    189. Yang JY, Zong CS, Xia W, Wei Y, Ali-Seyed M, Li Z, Broglio K, Berry DA, Hung MC. MDM2 promotes cell motility and invasiveness by regulating E-cadherin degradation. Mol Cell Biol. 2006 Oct; 26(19):7269-82. PMID: 16980628; PMCID: PMC1592879.
      Citations: 101     Fields:    Translation:HumansCells
    190. Berry DA. Bayesian statistics. Med Decis Making. 2006 Sep-Oct; 26(5):429-30. PMID: 16997921.
      Citations: 1     Fields:    
    191. Rincon M, Broadwater G, Harris L, Crocker A, Weaver D, Dressler L, Berry D, Sutton L, Michaelson R, Messino M, Kirshner J, Fleming G, Winer E, Hudis C, Appel S, Norton L, Muss H, Cancer and Leukemia Group B. Interleukin-6, multidrug resistance protein-1 expression and response to paclitaxel in women with metastatic breast cancer: results of cancer and leukemia group B trial 159806. Breast Cancer Res Treat. 2006 Dec; 100(3):301-8. PMID: 16773437.
      Citations: 9     Fields:    Translation:Humans
    192. Berry DA, Cirrincione C, Henderson IC, Citron ML, Budman DR, Goldstein LJ, Martino S, Perez EA, Muss HB, Norton L, Hudis C, Winer EP. Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer. JAMA. 2006 Apr 12; 295(14):1658-67. PMID: 16609087; PMCID: PMC1459540.
      Citations: 214     Fields:    Translation:Humans
    193. Chen S, Iversen ES, Friebel T, Finkelstein D, Weber BL, Eisen A, Peterson LE, Schildkraut JM, Isaacs C, Peshkin BN, Corio C, Leondaridis L, Tomlinson G, Dutson D, Kerber R, Amos CI, Strong LC, Berry DA, Euhus DM, Parmigiani G. Characterization of BRCA1 and BRCA2 mutations in a large United States sample. J Clin Oncol. 2006 Feb 20; 24(6):863-71. PMID: 16484695; PMCID: PMC2323978.
      Citations: 119     Fields:    Translation:Humans
    194. Berry DA, Inoue L, Shen Y, Venier J, Cohen D, Bondy M, Theriault R, Munsell MF. Modeling the impact of treatment and screening on U.S. breast cancer mortality: a Bayesian approach. J Natl Cancer Inst Monogr. 2006; (36):30-6. PMID: 17032892.
      Citations: 42     Fields:    Translation:HumansPHPublic Health
    195. Harris LN, Broadwater G, Lin NU, Miron A, Schnitt SJ, Cowan D, Lara J, Bleiweiss I, Berry D, Ellis M, Hayes DF, Winer EP, Dressler L. Molecular subtypes of breast cancer in relation to paclitaxel response and outcomes in women with metastatic disease: results from CALGB 9342. Breast Cancer Res. 2006; 8(6):R66. PMID: 17129383; PMCID: PMC1797029.
      Citations: 54     Fields:    Translation:Humans
    196. Johnson C, Peterson SK, Turley JP, Ensor J, Amos C, Spitz M, Levin B, Berry D. Strategies to improve healthcare websites. AMIA Annu Symp Proc. 2006; 969. PMID: 17238588; PMCID: PMC1839686.
      Citations:    Fields:    Translation:Humans
    197. Berry DA. Bayesian clinical trials. Nat Rev Drug Discov. 2006 Jan; 5(1):27-36. PMID: 16485344.
      Citations: 183     Fields:    
    198. Huang X, Biswas S, Estey EH, Berry DA. Building and validating a prognostic index for biomarker studies. Cancer Biomark. 2006; 2(3-4):97-101. PMID: 17192064.
      Citations: 1     Fields:    Translation:Humans
    199. Biswas S, Lin S, Berry DA. A new Bayesian approach incorporating covariate information for heterogeneity and its comparison with HLOD. BMC Genet. 2005 Dec 30; 6 Suppl 1:S138. PMID: 16451597; PMCID: PMC1866798.
      Citations: 1     Fields:    Translation:HumansCells
    200. Paci E, Ponti A, Crocetti E, Zappa M, Segnan N. Re: Role of detection method in predicting breast cancer survival: analysis of randomized screening trials. J Natl Cancer Inst. 2005 Dec 21; 97(24):1853-4; author reply 1854. PMID: 16368949.
      Citations:    Fields:    Translation:HumansPHPublic Health
    201. Clarke M, Collins R, Darby S, Davies C, Elphinstone P, Evans V, Godwin J, Gray R, Hicks C, James S, MacKinnon E, McGale P, McHugh T, Peto R, Taylor C, Wang Y, Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005 Dec 17; 366(9503):2087-106. PMID: 16360786.
      Citations: 1274     Fields:    Translation:Humans
    202. Rouzier R, Pusztai L, Delaloge S, Gonzalez-Angulo AM, Andre F, Hess KR, Buzdar AU, Garbay JR, Spielmann M, Mathieu MC, Symmans WF, Wagner P, Atallah D, Valero V, Berry DA, Hortobagyi GN. Nomograms to predict pathologic complete response and metastasis-free survival after preoperative chemotherapy for breast cancer. J Clin Oncol. 2005 Nov 20; 23(33):8331-9. PMID: 16293864.
      Citations: 82     Fields:    Translation:Humans
    203. Berry DA, Cronin KA, Plevritis SK, Fryback DG, Clarke L, Zelen M, Mandelblatt JS, Yakovlev AY, Habbema JD, Feuer EJ, Cancer Intervention and Surveillance Modeling Network (CISNET) Collaborators. Effect of screening and adjuvant therapy on mortality from breast cancer. N Engl J Med. 2005 Oct 27; 353(17):1784-92. PMID: 16251534.
      Citations: 762     Fields:    Translation:HumansPHPublic Health
    204. Biswas S, Berry DA. Determining joint carrier probabilities of cancer-causing genes using Markov chain Monte Carlo methods. Genet Epidemiol. 2005 Sep; 29(2):141-54. PMID: 16025444.
      Citations: 2     Fields:    Translation:Humans
    205. Shen Y, Yang Y, Inoue LY, Munsell MF, Miller AB, Berry DA. Role of detection method in predicting breast cancer survival: analysis of randomized screening trials. J Natl Cancer Inst. 2005 Aug 17; 97(16):1195-203. PMID: 16106024.
      Citations: 75     Fields:    Translation:HumansPHPublic Health
    206. Dressler LG, Berry DA, Broadwater G, Cowan D, Cox K, Griffin S, Miller A, Tse J, Novotny D, Persons DL, Barcos M, Henderson IC, Liu ET, Thor A, Budman D, Muss H, Norton L, Hayes DF. Comparison of HER2 status by fluorescence in situ hybridization and immunohistochemistry to predict benefit from dose escalation of adjuvant doxorubicin-based therapy in node-positive breast cancer patients. J Clin Oncol. 2005 Jul 01; 23(19):4287-97. PMID: 15994142.
      Citations: 31     Fields:    Translation:Humans
    207. Berry DA. Clinical trials: is the Bayesian approach ready for prime time? Yes! Stroke. 2005 Jul; 36(7):1621-2. PMID: 15947276.
      Citations: 5     Fields:    Translation:Humans
    208. Berry DA. The Bayesian principle: can we adapt? Stroke. 2005 Jul; 36(7):1623-4. PMID: 15947273.
      Citations: 2     Fields:    Translation:Humans
    209. Jimenez C, Yang Y, Kim HW, Al-Sagier F, Berry DA, El-Naggar AK, Patel S, Vassilopoulou-Sellin R, Gagel RF. Primary hyperparathyroidism and osteosarcoma: examination of a large cohort identifies three cases of fibroblastic osteosarcoma. J Bone Miner Res. 2005 Sep; 20(9):1562-8. PMID: 16059628.
      Citations: 7     Fields:    Translation:Humans
    210. Krams M, Lees KR, Berry DA. The past is the future: innovative designs in acute stroke therapy trials. Stroke. 2005 Jun; 36(6):1341-7. PMID: 15879340.
      Citations: 5     Fields:    Translation:Humans
    211. Muss HB, Woolf S, Berry D, Cirrincione C, Weiss RB, Budman D, Wood WC, Henderson IC, Hudis C, Winer E, Cohen H, Wheeler J, Norton L, Cancer and Leukemia Group B. Adjuvant chemotherapy in older and younger women with lymph node-positive breast cancer. JAMA. 2005 Mar 02; 293(9):1073-81. PMID: 15741529.
      Citations: 112     Fields:    Translation:Humans
    212. Buzdar AU, Ibrahim NK, Francis D, Booser DJ, Thomas ES, Theriault RL, Pusztai L, Green MC, Arun BK, Giordano SH, Cristofanilli M, Frye DK, Smith TL, Hunt KK, Singletary SE, Sahin AA, Ewer MS, Buchholz TA, Berry D, Hortobagyi GN. Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. J Clin Oncol. 2005 Jun 01; 23(16):3676-85. PMID: 15738535.
      Citations: 311     Fields:    Translation:HumansCTClinical Trials
    213. Lipscomb B, Ma G, Berry DA. Bayesian predictions of final outcomes: regulatory approval of a spinal implant. Clin Trials. 2005; 2(4):325-33; discussion 334-9, 364-78. PMID: 16281431.
      Citations: 4     Fields:    Translation:HumansPHPublic Health
    214. Johnson C, Ensor J, Amos C, Spitz M, Peterson S, Levin B, Berry DA. An informatics tool to assess colon cancer risk. AMIA Annu Symp Proc. 2005; 998. PMID: 16779285; PMCID: PMC1560488.
      Citations: 1     Fields:    Translation:Humans
    215. Berry DA. Introduction to Bayesian methods III: use and interpretation of Bayesian tools in design and analysis. Clin Trials. 2005; 2(4):295-300; discussion 301-4, 364-78. PMID: 16281428.
      Citations: 18     Fields:    Translation:Humans
    216. Berry DA, Wright D, Xie C, Seltzer JD, Smith JS. Using molecular sizes of simple sequence repeats vs. discrete binned data in assessing probability of ancestry: application to maize hybrids. Genetics. 2005 May; 170(1):365-74. PMID: 15466437; PMCID: PMC1449699.
      Citations:    Fields:    Translation:AnimalsCells
    217. Hughes KS, Schnaper LA, Berry D, Cirrincione C, McCormick B, Shank B, Wheeler J, Champion LA, Smith TJ, Smith BL, Shapiro C, Muss HB, Winer E, Hudis C, Wood W, Sugarbaker D, Henderson IC, Norton L, Cancer and Leukemia Group B, Radiation Therapy Oncology Group, Eastern Cooperative Oncology Group. Lumpectomy plus tamoxifen with or without irradiation in women 70 years of age or older with early breast cancer. N Engl J Med. 2004 Sep 02; 351(10):971-7. PMID: 15342805.
      Citations: 188     Fields:    Translation:HumansCTClinical Trials
    218. Buchholz TA, Huang EH, Berry D, Pusztai L, Strom EA, McNeese MD, Perkins GH, Schechter NR, Kuerer HM, Buzdar AU, Valero V, Hunt KK, Hortobagyi GN, Sahin AA. Her2/neu-positive disease does not increase risk of locoregional recurrence for patients treated with neoadjuvant doxorubicin-based chemotherapy, mastectomy, and radiotherapy. Int J Radiat Oncol Biol Phys. 2004 Aug 01; 59(5):1337-42. PMID: 15275718.
      Citations: 9     Fields:    Translation:Humans
    219. Winer EP, Berry DA, Woolf S, Duggan D, Kornblith A, Harris LN, Michaelson RA, Kirshner JA, Fleming GF, Perry MC, Graham ML, Sharp SA, Keresztes R, Henderson IC, Hudis C, Muss H, Norton L. Failure of higher-dose paclitaxel to improve outcome in patients with metastatic breast cancer: cancer and leukemia group B trial 9342. J Clin Oncol. 2004 Jun 01; 22(11):2061-8. PMID: 15169793.
      Citations: 74     Fields:    Translation:HumansCTClinical Trials
    220. Berry SM, Berry DA. Accounting for multiplicities in assessing drug safety: a three-level hierarchical mixture model. Biometrics. 2004 Jun; 60(2):418-26. PMID: 15180667.
      Citations: 26     Fields:    Translation:Humans
    221. Berry D. Commentary: screening mammography: a decision analysis. Int J Epidemiol. 2004 Feb; 33(1):68; discussion 69-73. PMID: 15075148.
      Citations: 4     Fields:    Translation:HumansPHPublic Health
    222. Hennekens CH, Sacks FM, Tonkin A, Jukema JW, Byington RP, Pitt B, Berry DA, Berry SM, Ford NF, Walker AJ, Natarajan K, Sheng-Lin C, Fiedorek FT, Belder R. Additive benefits of pravastatin and aspirin to decrease risks of cardiovascular disease: randomized and observational comparisons of secondary prevention trials and their meta-analyses. Arch Intern Med. 2004 Jan 12; 164(1):40-4. PMID: 14718320.
      Citations: 24     Fields:    Translation:Humans
    223. Kimmick G, Ratain MJ, Berry D, Woolf S, Norton L, Muss HB, Cancer and Leukemia Group B (CALGB 9041). Subcutaneously administered recombinant human interleukin-2 and interferon alfa-2a for advanced breast cancer: a phase II study of the Cancer and Leukemia Group B (CALGB 9041). Invest New Drugs. 2004 Jan; 22(1):83-9. PMID: 14707498.
      Citations: 4     Fields:    Translation:HumansCTClinical Trials
    224. Berry DA, Seltzer JD, Xie C, Wright DL, Jones ES, Sebastian S, Smith JS. Assessing probability of ancestry using simple sequence repeat profiles: applications to maize inbred lines and soybean varieties. Genetics. 2003 Sep; 165(1):331-42. PMID: 14504240; PMCID: PMC1462747.
      Citations: 1     Fields:    Translation:AnimalsCells
    225. Singletary SE, Allred C, Ashley P, Bassett LW, Berry D, Bland KI, Borgen PI, Clark GM, Edge SB, Hayes DF, Hughes LL, Hutter RV, Morrow M, Page DL, Recht A, Theriault RL, Thor A, Weaver DL, Wieand HS, Greene FL. Staging system for breast cancer: revisions for the 6th edition of the AJCC Cancer Staging Manual. Surg Clin North Am. 2003 Aug; 83(4):803-19. PMID: 12875597.
      Citations: 120     Fields:    Translation:Humans
    226. Berry DA, Berry SM, McKellar J, Pearson TA. Comparison of the dose-response relationships of 2 lipid-lowering agents: a Bayesian meta-analysis. Am Heart J. 2003 Jun; 145(6):1036-45. PMID: 12796760.
      Citations: 3     Fields:    Translation:Humans
    227. Parnes HL, Cirrincione C, Aisner J, Berry DA, Allen SL, Abrams J, Chuang E, Cooper MR, Perry MC, Duggan DB, Szatrowski TP, Henderson IC, Norton L, Cancer and Leukemia Group B. Phase III study of cyclophosphamide, doxorubicin, and fluorouracil (CAF) plus leucovorin versus CAF for metastatic breast cancer: Cancer and Leukemia Group B 9140. J Clin Oncol. 2003 May 01; 21(9):1819-24. PMID: 12721259.
      Citations: 9     Fields:    Translation:HumansCTClinical Trials
    228. Weiss RB, Woolf SH, Demakos E, Holland JF, Berry DA, Falkson G, Cirrincione CT, Robbins A, Bothun S, Henderson IC, Norton L, Cancer and Leukemia Group B. Natural history of more than 20 years of node-positive primary breast carcinoma treated with cyclophosphamide, methotrexate, and fluorouracil-based adjuvant chemotherapy: a study by the Cancer and Leukemia Group B. J Clin Oncol. 2003 May 01; 21(9):1825-35. PMID: 12721260.
      Citations: 15     Fields:    Translation:HumansCTClinical Trials
    229. Giles FJ, Kantarjian HM, Cortes JE, Garcia-Manero G, Verstovsek S, Faderl S, Thomas DA, Ferrajoli A, O'Brien S, Wathen JK, Xiao LC, Berry DA, Estey EH. Adaptive randomized study of idarubicin and cytarabine versus troxacitabine and cytarabine versus troxacitabine and idarubicin in untreated patients 50 years or older with adverse karyotype acute myeloid leukemia. J Clin Oncol. 2003 May 01; 21(9):1722-7. PMID: 12721247.
      Citations: 15     Fields:    Translation:HumansCTClinical Trials
    230. Henderson IC, Berry DA, Demetri GD, Cirrincione CT, Goldstein LJ, Martino S, Ingle JN, Cooper MR, Hayes DF, Tkaczuk KH, Fleming G, Holland JF, Duggan DB, Carpenter JT, Frei E, Schilsky RL, Wood WC, Muss HB, Norton L. Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol. 2003 Mar 15; 21(6):976-83. PMID: 12637460.
      Citations: 315     Fields:    Translation:HumansCTClinical Trials
    231. Citron ML, Berry DA, Cirrincione C, Hudis C, Winer EP, Gradishar WJ, Davidson NE, Martino S, Livingston R, Ingle JN, Perez EA, Carpenter J, Hurd D, Holland JF, Smith BL, Sartor CI, Leung EH, Abrams J, Schilsky RL, Muss HB, Norton L. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol. 2003 Apr 15; 21(8):1431-9. PMID: 12668651.
      Citations: 412     Fields:    Translation:HumansCTClinical Trials
    232. Berry DA. General keynote: clinical trial design. Gynecol Oncol. 2003 Jan; 88(1 Pt 2):S114-6; S122-3. PMID: 12586099.
      Citations:    Fields:    Translation:Humans
    233. Inoue LY, Thall PF, Berry DA. Seamlessly expanding a randomized phase II trial to phase III. Biometrics. 2002 Dec; 58(4):823-31. PMID: 12495136.
      Citations: 23     Fields:    Translation:HumansCells
    234. Cremin C, Wong N, Buzaglo K, Foulkes W, Paradis AJ. Nonovarian pelvic cancers in BRCA1/2 mutation carriers and the BRCAPRO statistical model. J Clin Oncol. 2002 Sep 15; 20(18):3936; author reply 3936-7. PMID: 12228218.
      Citations: 1     Fields:    Translation:Humans
    235. Singletary SE, Allred C, Ashley P, Bassett LW, Berry D, Bland KI, Borgen PI, Clark G, Edge SB, Hayes DF, Hughes LL, Hutter RV, Morrow M, Page DL, Recht A, Theriault RL, Thor A, Weaver DL, Wieand HS, Greene FL. Revision of the American Joint Committee on Cancer staging system for breast cancer. J Clin Oncol. 2002 Sep 01; 20(17):3628-36. PMID: 12202663.
      Citations: 293     Fields:    Translation:Humans
    236. Berry DA, Seltzer JD, Xie C, Wright DL, Smith JS. Assessing probability of ancestry using simple sequence repeat profiles: applications to maize hybrids and inbreds. Genetics. 2002 Jun; 161(2):813-24. PMID: 12072476; PMCID: PMC1462128.
      Citations: 5     Fields:    Translation:AnimalsCells
    237. Berry DA, Iversen ES, Gudbjartsson DF, Hiller EH, Garber JE, Peshkin BN, Lerman C, Watson P, Lynch HT, Hilsenbeck SG, Rubinstein WS, Hughes KS, Parmigiani G. BRCAPRO validation, sensitivity of genetic testing of BRCA1/BRCA2, and prevalence of other breast cancer susceptibility genes. J Clin Oncol. 2002 Jun 01; 20(11):2701-12. PMID: 12039933.
      Citations: 152     Fields:    Translation:Humans
    238. Buzdar AU, Singletary SE, Valero V, Booser DJ, Ibrahim NK, Rahman Z, Theriault RL, Walters R, Rivera E, Smith TL, Holmes FA, Hoy E, Frye DK, Manuel N, Kau SW, McNeese MD, Strom E, Thomas E, Hunt K, Ames F, Berry D, Hortobagyi GN. Evaluation of paclitaxel in adjuvant chemotherapy for patients with operable breast cancer: preliminary data of a prospective randomized trial. Clin Cancer Res. 2002 May; 8(5):1073-9. PMID: 12006521.
      Citations: 28     Fields:    Translation:HumansCTClinical Trials
    239. Petros WP, Broadwater G, Berry D, Jones RB, Vredenburgh JJ, Gilbert CJ, Gibbs JP, Colvin OM, Peters WP. Association of high-dose cyclophosphamide, cisplatin, and carmustine pharmacokinetics with survival, toxicity, and dosing weight in patients with primary breast cancer. Clin Cancer Res. 2002 Mar; 8(3):698-705. PMID: 11895898.
      Citations: 10     Fields:    Translation:HumansCTClinical Trials
    240. Guidi AJ, Berry DA, Broadwater G, Helmchen B, Bleiweiss IJ, Budman DR, Henderson IC, Norton L, Hayes DF. Association of angiogenesis and disease outcome in node-positive breast cancer patients treated with adjuvant cyclophosphamide, doxorubicin, and fluorouracil: a Cancer and Leukemia Group B correlative science study from protocols 8541/8869. J Clin Oncol. 2002 Feb 01; 20(3):732-42. PMID: 11821455.
      Citations: 2     Fields:    Translation:HumansCTClinical Trials
    241. Berry DA, Broadwater G, Klein JP, Antman K, Aisner J, Bitran J, Costanza M, Freytes CO, Stadtmauer E, Gale RP, Henderson IC, Lazarus HM, McCarthy PL, Norton L, Parnes H, Pecora A, Perry MC, Rowlings P, Spitzer G, Horowitz MM. High-dose versus standard chemotherapy in metastatic breast cancer: comparison of Cancer and Leukemia Group B trials with data from the Autologous Blood and Marrow Transplant Registry. J Clin Oncol. 2002 Feb 01; 20(3):743-50. PMID: 11821456.
      Citations: 8     Fields:    Translation:HumansCTClinical Trials
    242. Skinner CS, Schildkraut JM, Berry D, Calingaert B, Marcom PK, Sugarman J, Winer EP, Iglehart JD, Futreal PA, Rimer BK. Pre-counseling education materials for BRCA testing: does tailoring make a difference? Genet Test. 2002; 6(2):93-105. PMID: 12215248.
      Citations: 29     Fields:    Translation:Humans
    243. Hayes DF, Yamauchi H, Broadwater G, Cirrincione CT, Rodrigue SP, Berry DA, Younger J, Panasci LL, Millard F, Duggan DB, Norton L, Henderson IC, Cancer and Leukemia Group B. Circulating HER-2/erbB-2/c-neu (HER-2) extracellular domain as a prognostic factor in patients with metastatic breast cancer: Cancer and Leukemia Group B Study 8662. Clin Cancer Res. 2001 Sep; 7(9):2703-11. PMID: 11555582.
      Citations: 17     Fields:    Translation:Humans
    244. Pecora AL, Lazarus HM, Stadtmauer EA, Winter J, Van Vliet A, Berry D, Gray R, Jennis A, Goldberg S, Cooper BW, Preti R. Effect of induction chemotherapy and tandem cycles of high-dose chemotherapy on outcomes in autologous stem cell transplant for metastatic breast cancer. Bone Marrow Transplant. 2001 Jun; 27(12):1245-53. PMID: 11548842.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    245. Harris LN, Liotcheva V, Broadwater G, Ramirez MJ, Maimonis P, Anderson S, Everett T, Harpole D, Moore MB, Berry DA, Rizzeri D, Vredenburgh JJ, Bentley RC. Comparison of methods of measuring HER-2 in metastatic breast cancer patients treated with high-dose chemotherapy. J Clin Oncol. 2001 Mar 15; 19(6):1698-706. PMID: 11250999.
      Citations: 16     Fields:    Translation:Humans
    246. Berry DA, Muss HB, Thor AD, Dressler L, Liu ET, Broadwater G, Budman DR, Henderson IC, Barcos M, Hayes D, Norton L. HER-2/neu and p53 expression versus tamoxifen resistance in estrogen receptor-positive, node-positive breast cancer. J Clin Oncol. 2000 Oct 15; 18(20):3471-9. PMID: 11032587.
      Citations: 39     Fields:    Translation:Humans
    247. Guidi AJ, Berry DA, Broadwater G, Perloff M, Norton L, Barcos MP, Hayes DF. Association of angiogenesis in lymph node metastases with outcome of breast cancer. J Natl Cancer Inst. 2000 Mar 15; 92(6):486-92. PMID: 10716967.
      Citations: 18     Fields:    Translation:Humans
    248. Blackwell K, Haroon Z, Broadwater G, Berry D, Harris L, Iglehart JD, Dewhirst M, Greenberg C. Plasma D-dimer levels in operable breast cancer patients correlate with clinical stage and axillary lymph node status. J Clin Oncol. 2000 Feb; 18(3):600-8. PMID: 10653875.
      Citations: 53     Fields:    Translation:HumansCTClinical Trials
    249. Rizzieri DA, Vredenburgh JJ, Jones R, Ross M, Shpall EJ, Hussein A, Broadwater G, Berry D, Petros WP, Gilbert C, Affronti ML, Coniglio D, Rubin P, Elkordy M, Long GD, Chao NJ, Peters WP. Prognostic and predictive factors for patients with metastatic breast cancer undergoing aggressive induction therapy followed by high-dose chemotherapy with autologous stem-cell support. J Clin Oncol. 1999 Oct; 17(10):3064-74. PMID: 10506601.
      Citations: 12     Fields:    Translation:HumansCTClinical Trials
    250. Hryniuk W. Re: Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer. J Natl Cancer Inst. 1999 Aug 18; 91(16):1425. PMID: 10451457.
      Citations:    Fields:    Translation:Humans
    251. Ashih H, Gustilo-Ashby T, Myers ER, Andrews J, Clarke-Pearson DL, Berry D, Berchuck A. Cost-effectiveness of treatment of early stage endometrial cancer. Gynecol Oncol. 1999 Aug; 74(2):208-16. PMID: 10419733.
      Citations: 2     Fields:    Translation:Humans
    252. Parmigiani G, Berry DA, Winer EP, Tebaldi C, Iglehart JD, Prosnitz LR. Is axillary lymph node dissection indicated for early-stage breast cancer? A decision analysis. J Clin Oncol. 1999 May; 17(5):1465-73. PMID: 10334532.
      Citations: 7     Fields:    Translation:Humans
    253. Costanza ME, Weiss RB, Henderson IC, Norton L, Berry DA, Cirrincione C, Winer E, Wood WC, Frei E, McIntyre OR, Schilsky RL. Safety and efficacy of using a single agent or a phase II agent before instituting standard combination chemotherapy in previously untreated metastatic breast cancer patients: report of a randomized study--Cancer and Leukemia Group B 8642. J Clin Oncol. 1999 May; 17(5):1397-406. PMID: 10334524.
      Citations: 4     Fields:    Translation:HumansCTClinical Trials
    254. Cameron DA, Leonard RC. Re: erbB-2, p53, and efficacy of adjuvant therapy in lymph node-positive breast cancer. J Natl Cancer Inst. 1999 Apr 21; 91(8):728-9. PMID: 10218517.
      Citations:    Fields:    Translation:Humans
    255. Bluman LG, Rimer BK, Berry DA, Borstelmann N, Iglehart JD, Regan K, Schildkraut J, Winer EP. Attitudes, knowledge, and risk perceptions of women with breast and/or ovarian cancer considering testing for BRCA1 and BRCA2. J Clin Oncol. 1999 Mar; 17(3):1040-6. PMID: 10071299.
      Citations: 31     Fields:    Translation:HumansCTClinical Trials
    256. Kopans DB, Halpern E. Re: Benefits and risks of screening mammography for women in their forties: a statistical appraisal. J Natl Cancer Inst. 1999 Feb 17; 91(4):382-4. PMID: 10050875.
      Citations: 1     Fields:    Translation:Humans
    257. Vollmer RT. Re: Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer. J Natl Cancer Inst. 1999 Feb 03; 91(3):286-7. PMID: 10037109.
      Citations:    Fields:    Translation:Humans
    258. Abrams J, Aisner J, Cirrincione C, Berry DA, Muss HB, Cooper MR, Henderson IC, Panasci L, Kirshner J, Ellerton J, Norton L. Dose-response trial of megestrol acetate in advanced breast cancer: cancer and leukemia group B phase III study 8741. J Clin Oncol. 1999 Jan; 17(1):64-73. PMID: 10458219.
      Citations: 14     Fields:    Translation:HumansCTClinical Trials
    259. Claus EB, Schildkraut J, Iversen ES, Berry D, Parmigiani G. Effect of BRCA1 and BRCA2 on the association between breast cancer risk and family history. J Natl Cancer Inst. 1998 Dec 02; 90(23):1824-9. PMID: 9839523.
      Citations: 27     Fields:    Translation:Humans
    260. Berry DA. Benefits and risks of screening mammography for women in their forties: a statistical appraisal. J Natl Cancer Inst. 1998 Oct 07; 90(19):1431-9. PMID: 9776408.
      Citations: 14     Fields:    Translation:HumansPHPublic Health
    261. Tengs TO, Winer EP, Paddock S, Aguilar-Chavez O, Berry DA. Testing for the BRCA1 and BRCA2 breast-ovarian cancer susceptibility genes: a decision analysis. Med Decis Making. 1998 Oct-Dec; 18(4):365-75. PMID: 10372578.
      Citations: 4     Fields:    Translation:Humans
    262. Thor AD, Berry DA, Budman DR, Muss HB, Kute T, Henderson IC, Barcos M, Cirrincione C, Edgerton S, Allred C, Norton L, Liu ET. erbB-2, p53, and efficacy of adjuvant therapy in lymph node-positive breast cancer. J Natl Cancer Inst. 1998 Sep 16; 90(18):1346-60. PMID: 9747866.
      Citations: 82     Fields:    Translation:HumansCTClinical Trials
    263. Iglehart JD, Miron A, Rimer BK, Winer EP, Berry D, Shildkraut MJ. Overestimation of hereditary breast cancer risk. Ann Surg. 1998 Sep; 228(3):375-84. PMID: 9742920; PMCID: PMC1191495.
      Citations: 3     Fields:    Translation:Humans
    264. Budman DR, Berry DA, Cirrincione CT, Henderson IC, Wood WC, Weiss RB, Ferree CR, Muss HB, Green MR, Norton L, Frei E. Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer. The Cancer and Leukemia Group B. J Natl Cancer Inst. 1998 Aug 19; 90(16):1205-11. PMID: 9719081.
      Citations: 124     Fields:    Translation:HumansCTClinical Trials
    265. Berry DA. Screening mammography for women in their forties. Breast Dis. 1998 Aug; 10(3-4):23-32. PMID: 15687561.
      Citations: 2     Fields:    
    266. Berry DA, Parmigiani G. Assessing the benefits of testing for breast cancer susceptibility genes: a decision analysis. Breast Dis. 1998 Apr; 10(1-2):115-25. PMID: 15687554.
      Citations: 2     Fields:    
    267. Laughlin MJ, McGaughey DS, Crews JR, Chao NJ, Rizzieri D, Ross M, Gockerman J, Cirrincione C, Berry D, Mills L, Defusco P, LeGrand S, Peters WP, Vredenburgh JJ. Secondary myelodysplasia and acute leukemia in breast cancer patients after autologous bone marrow transplant. J Clin Oncol. 1998 Mar; 16(3):1008-12. PMID: 9508184.
      Citations: 8     Fields:    Translation:Humans
    268. Peters KG, Coogan A, Berry D, Marks J, Iglehart JD, Kontos CD, Rao P, Sankar S, Trogan E. Expression of Tie2/Tek in breast tumour vasculature provides a new marker for evaluation of tumour angiogenesis. Br J Cancer. 1998; 77(1):51-6. PMID: 9459145; PMCID: PMC2151265.
      Citations: 28     Fields:    Translation:Humans
    269. Fisher DC, Vredenburgh JJ, Petros WP, Hussein A, Berry DA, Elkordy M, Rubin P, Gilbert CJ, Peters WP. Reduced mortality following bone marrow transplantation for breast cancer with the addition of peripheral blood progenitor cells is due to a marked reduction in veno-occlusive disease of the liver. Bone Marrow Transplant. 1998 Jan; 21(2):117-22. PMID: 9489626.
      Citations: 2     Fields:    Translation:HumansCTClinical Trials
    270. Gilbert CJ, Petros WP, Vredenburgh J, Hussein A, Ross M, Rubin P, Fehdrau R, Cavanaugh C, Berry D, McKinstry C, Peters WP. Pharmacokinetic interaction between ondansetron and cyclophosphamide during high-dose chemotherapy for breast cancer. Cancer Chemother Pharmacol. 1998; 42(6):497-503. PMID: 9788577.
      Citations: 12     Fields:    Translation:HumansCTClinical Trials
    271. Parmigiani G, Berry D, Aguilar O. Determining carrier probabilities for breast cancer-susceptibility genes BRCA1 and BRCA2. Am J Hum Genet. 1998 Jan; 62(1):145-58. PMID: 9443863; PMCID: PMC1376797.
      Citations: 232     Fields:    Translation:Humans
    272. Vredenburgh JJ, Silva O, Broadwater G, Berry D, DeSombre K, Tyer C, Petros WP, Peters WP, Bast RC. The significance of tumor contamination in the bone marrow from high-risk primary breast cancer patients treated with high-dose chemotherapy and hematopoietic support. Biol Blood Marrow Transplant. 1997 Jun; 3(2):91-7. PMID: 9267669.
      Citations: 3     Fields:    Translation:HumansCTClinical Trials
    273. Alpert LC, Schecter RL, Berry DA, Melnychuk D, Peters WP, Caruso JA, Townsend AJ, Batist G. Relation of glutathione S-transferase alpha and mu isoforms to response to therapy in human breast cancer. Clin Cancer Res. 1997 May; 3(5):661-7. PMID: 9815734.
      Citations: 2     Fields:    Translation:Humans
    274. Roach M, Cirrincione C, Budman D, Hayes D, Berry D, Younger J, Hart R, Henderson IC. Race and survival from breast cancer: based on Cancer and Leukemia Group B trial 8541. Cancer J Sci Am. 1997 Mar-Apr; 3(2):107-12. PMID: 9099461.
      Citations: 8     Fields:    Translation:HumansCTClinical Trials
    275. Berry DA, Parmigiani G, Sanchez J, Schildkraut J, Winer E. Probability of carrying a mutation of breast-ovarian cancer gene BRCA1 based on family history. J Natl Cancer Inst. 1997 Feb 05; 89(3):227-38. PMID: 9017003.
      Citations: 91     Fields:    Translation:Humans
    276. Berry DA. When is a confirmatory randomized clinical trial needed? J Natl Cancer Inst. 1996 Nov 20; 88(22):1606-7. PMID: 8931598.
      Citations: 1     Fields:    Translation:Humans
    277. Hussein AM, Petros WP, Ross M, Vredenburgh JJ, Affrontil ML, Jones RB, Shpall EJ, Rubin P, Elkordy M, Gilbert C, Gupton C, Egorin MJ, Soper J, Berchuck A, Clarke-Person D, Berry DA, Peters WP. A phase I/II study of high-dose cyclophosphamide, cisplatin, and thioTEPA followed by autologous bone marrow and granulocyte colony-stimulating factor-primed peripheral-blood progenitor cells in patients with advanced malignancies. Cancer Chemother Pharmacol. 1996; 37(6):561-8. PMID: 8612310.
      Citations: 4     Fields:    Translation:HumansCTClinical Trials
    278. Kute TE, Quadri Y, Muss H, Zbieranski N, Cirrincione C, Berry DA, Barcos M, Thor AP, Liu E, Koerner F, et al. Flow cytometry in node-positive breast cancer: cancer and leukemia group B protocol 8869. Cytometry. 1995 Dec 15; 22(4):297-306. PMID: 8749780.
      Citations: 3     Fields:    Translation:HumansCellsCTClinical Trials
    279. Costanza ME, Berry D, Henderson IC, Ratain MJ, Wu K, Shapiro C, Duggan D, Kalra J, Berkowitz I, Lyss AP. Amonafide: An active agent in the treatment of previously untreated advanced breast cancer--a cancer and leukemia group B study (CALGB 8642). Clin Cancer Res. 1995 Jul; 1(7):699-704. PMID: 9816035.
      Citations: 12     Fields:    Translation:HumansCTClinical Trials
    280. Rosner GL, Berry DA. A Bayesian group sequential design for a multiple arm randomized clinical trial. Stat Med. 1995 Feb 28; 14(4):381-94. PMID: 7746978.
      Citations: 3     Fields:    Translation:Humans
    281. Berry DA, Eick SG. Adaptive assignment versus balanced randomization in clinical trials: a decision analysis. Stat Med. 1995 Feb 15; 14(3):231-46. PMID: 7724909.
      Citations: 52     Fields:    Translation:Humans
    282. Berry DA. Decision analysis and Bayesian methods in clinical trials. Cancer Treat Res. 1995; 75:125-54. PMID: 7640161.
      Citations: 1     Fields:    Translation:Humans
    283. Perry JJ, Berry DA, Weiss RB, Hayes DM, Duggan DB, Henderson IC. High dose toremifene for estrogen and progesterone receptor negative metastatic breast cancer: a phase II trial of the Cancer and Leukemia Group B (CALGB). Breast Cancer Res Treat. 1995; 36(1):35-40. PMID: 7579504.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    284. Berry DA, Wolff MC, Sack D. Decision making during a phase III randomized controlled trial. Control Clin Trials. 1994 Oct; 15(5):360-78. PMID: 8001357.
      Citations: 3     Fields:    Translation:HumansCellsCTClinical Trials
    285. George SL, Li C, Berry DA, Green MR. Stopping a clinical trial early: frequentist and Bayesian approaches applied to a CALGB trial in non-small-cell lung cancer. Stat Med. 1994 Jul 15-30; 13(13-14):1313-27. PMID: 7973212.
      Citations: 4     Fields:    Translation:HumansCTClinical Trials
    286. Muss HB, Thor AD, Berry DA, Kute T, Liu ET, Koerner F, Cirrincione CT, Budman DR, Wood WC, Barcos M, et al. c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer. N Engl J Med. 1994 May 05; 330(18):1260-6. PMID: 7908410.
      Citations: 135     Fields:    Translation:HumansCellsCTClinical Trials
    287. Marks JR, Humphrey PA, Wu K, Berry D, Bandarenko N, Kerns BJ, Iglehart JD. Overexpression of p53 and HER-2/neu proteins as prognostic markers in early stage breast cancer. Ann Surg. 1994 Apr; 219(4):332-41. PMID: 7909221; PMCID: PMC1243148.
      Citations: 22     Fields:    Translation:Humans
    288. Berry DA. Clinical research in the critical care environment. Crit Care Med. 1993 Sep; 21(9 Suppl):S400-2. PMID: 8365257.
      Citations:    Fields:    Translation:Humans
    289. Berry DA. A case for Bayesianism in clinical trials. Stat Med. 1993 Aug; 12(15-16):1377-93; discussion 1395-404. PMID: 8248653.
      Citations: 24     Fields:    
    290. Berry DA. Power of chronobiologic pilots: a statistician's opinion. Chronobiologia. 1993 Jul-Dec; 20(3-4):213-8. PMID: 8131670.
      Citations: 2     Fields:    Translation:Humans
    291. Berry DA. Transparent polyurethane film as a catheter dressing. JAMA. 1992 Nov 11; 268(18):2514-5. PMID: 1404814.
      Citations:    Fields:    Translation:Humans
    292. Berry DA. Subgroup analyses. Biometrics. 1990 Dec; 46(4):1227-30. PMID: 2085637.
      Citations: 8     Fields:    Translation:Humans
    293. Salerno DM, Gillingham KJ, Berry DA, Hodges M. A comparison of antiarrhythmic drugs for the suppression of ventricular ectopic depolarizations: a meta-analysis. Am Heart J. 1990 Aug; 120(2):340-53. PMID: 1696426.
      Citations: 9     Fields:    Translation:Humans
    294. Hillman D, Berry DA, Halberg J, Halberg F, Fern?ndez JR, Corn?lissen G. Bounded limits and statistical inference in chronobiometry. Prog Clin Biol Res. 1990; 341B:417-28. PMID: 2217334.
      Citations: 2     Fields:    Translation:Humans
    295. Berry DA. Monitoring accumulating data in a clinical trial. Biometrics. 1989 Dec; 45(4):1197-211. PMID: 2611322.
      Citations: 11     Fields:    Translation:Humans
    296. Holtzman JL, Weeks CE, Kvam DC, Berry DA, Mottonen L, Ekholm BP, Chang SF, Conard GJ. Identification of drug interactions by meta-analysis of premarketing trials: the effect of smoking on the pharmacokinetics and dosage requirements for flecainide acetate. Clin Pharmacol Ther. 1989 Jul; 46(1):1-8. PMID: 2501055.
      Citations: 6     Fields:    Translation:HumansCTClinical Trials
    297. Holtzman JL, Finley D, Mottonen L, Berry DA, Ekholm BP, Kvam DC, McQuinn RL, Miller AM. The pharmacodynamic and pharmacokinetic interaction between single doses of flecainide acetate and verapamil: effects on cardiac function and drug clearance. Clin Pharmacol Ther. 1989 Jul; 46(1):26-32. PMID: 2501057.
      Citations: 7     Fields:    Translation:Humans
    298. Van Eys J, Berry D, Crist W, Doering E, Fernbach D, Pullen J, Shuster J. Treatment intensity and outcome for children with acute lymphocytic leukemia of standard risk. A Pediatric Oncology Group Study. Cancer. 1989 Apr 15; 63(8):1466-71. PMID: 2924255.
      Citations: 5     Fields:    Translation:HumansCTClinical Trials
    299. van Eys J, Berry D, Crist W, Doering E, Fernbach D, Pullen J, Shuster J, Wharam M. A comparison of two regimens for high-risk acute lymphocytic leukemia in childhood. A Pediatric Oncology Group Study. Cancer. 1989 Jan 01; 63(1):23-9. PMID: 2910421.
      Citations: 3     Fields:    Translation:HumansCTClinical Trials
    300. Gitter MJ, Salerno DM, Berry DA, Fifield JH, Farmer CK. Variability of different methods for measurement of ECG intervals and ECG interval temporal variation. J Electrocardiol. 1989; 22 Suppl:125-6. PMID: 2614290.
      Citations:    Fields:    Translation:Humans
    301. Berry DA, Ho CH. One-sided sequential stopping boundaries for clinical trials: a decision-theoretic approach. Biometrics. 1988 Mar; 44(1):219-27. PMID: 3358990.
      Citations: 11     Fields:    
    302. Berry DA. Logarithmic transformations in ANOVA. Biometrics. 1987 Jun; 43(2):439-56. PMID: 3300800.
      Citations: 9     Fields:    Translation:HumansCTClinical Trials
    303. Holtzman JL, Kvam DC, Berry DA, Mottonen L, Borrell G, Harrison LI, Conard GJ. The pharmacodynamic and pharmacokinetic interaction of flecainide acetate with propranolol: effects on cardiac function and drug clearance. Eur J Clin Pharmacol. 1987; 33(1):97-9. PMID: 3121353.
      Citations:    Fields:    Translation:Humans
    304. Berry DA. Interim analyses in clinical research. Cancer Invest. 1987; 5(5):469-77. PMID: 3427509.
      Citations:    Fields:    Translation:Humans
    305. Holtzman JL, Finley D, Johnson B, Berry DA, Sirgo MA. The effects of single-dose atenolol, labetalol, and propranolol on cardiac and vascular function. Clin Pharmacol Ther. 1986 Sep; 40(3):268-73. PMID: 3742933.
      Citations: 2     Fields:    Translation:HumansCTClinical Trials
    306. Salerno DM, Granrud G, Sharkey P, Krejci J, Larson T, Erlien D, Berry D, Hodges M. Pharmacodynamics and side effects of flecainide acetate. Clin Pharmacol Ther. 1986 Jul; 40(1):101-7. PMID: 3720173.
      Citations: 15     Fields:    Translation:Humans
    307. Berry DA. Interim analyses in clinical trials: classical vs. Bayesian approaches. Stat Med. 1985 Oct-Dec; 4(4):521-6. PMID: 4089353.
      Citations: 14     Fields:    Translation:Humans
    308. Berry DA, Eaton ML, Ekholm BP, Fox TL. Assessing differential drug effect. Biometrics. 1984 Dec; 40(4):1109-15. PMID: 6398711.
      Citations: 4     Fields:    Translation:HumansCTClinical Trials
    309. Holtzman JL, Berry DA, Kvam DC, Mottonen L, Borrell G. Application of second-order polynomial equations to the study of pharmacodynamic interactions: the effect of flecainide acetate and propranolol on cardiac output and vascular resistance. J Pharmacol Exp Ther. 1984 Nov; 231(2):286-90. PMID: 6491982.
      Citations: 3     Fields:    Translation:Humans
    310. Berry DA, Fox TL. Regression analysis applied to PVC histories: a statistical procedure for evaluating antiarrhythmic drug efficacy. Stat Med. 1983 Jul-Sep; 2(3):331-43. PMID: 6359320.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    311. The neoadjuvant model is still the future for drug development in breast cancer. Clinical Cancer Research. 21:2911-2915.
    312. Comment. Statistical Science. 4:306-310.
    313. Herceptin plus chemotherapy combination in preoperative regimen may offer clinical benefit in early stage breast cancer. Cancer Biology and Therapy. 4.
    314. Reply. Clinical Trials. 6:394.
    315. Bayesian methods in phase III trials. Therapeutic Innovation and Regulatory Science. 25:345-368.
    316. In reply. Journal of Clinical Oncology. 21:4465-4466.
    317. Modified two-armed bandit strategies for certain clinical trials. Journal of the American Statistical Association. 73:339-345.
    318. Probabilities of winning a certain carnival game. American Statistician. 32:126-129.
    319. DISCRETE SEARCH WITH DIRECTIONAL INFORMATION. Operations Research. 34:470-477.
    320. Bandit problems with infinitely many arms. Annals of Statistics. 25:2103-2116.
    321. Choosing sample size for a clinical trial using decision analysis. Biometrika. 90:923-936.
    322. Biostatistics and Bioinformatics in Clinical Trials. 282-293.
    323. Bayesian model averaging in meta-analysis. Clinical Trials. 6:50-51.
    324. The cost effectiveness of testing for the BRCA1 and BRCA2 breast-ovarian cancer susceptibility genes. Disease Management and Clinical Outcomes. 2:15-24.
    325. Bayesian multiple comparisons using dirichlet process priors. Journal of the American Statistical Association. 93:1130-1139.
    326. Efficient dose-response finding strategies for acute neuroemergency treatments. 179-204.
    327. Relationship between bayesian and frequentist sample size determination. American Statistician. 59:79-87.
    328. Optimal adaptive randomized designs for clinical trials. Biometrika. 94:673-687.
    329. Reply to M. Moroni and U. De Giorgi et al. Journal of Clinical Oncology. 30:759-760.
    330. Genetic Susceptibility and Survival. Journal of the American Statistical Association. 95:28-42.
    331. Drs. Berry and Esserman reply. New England Journal of Medicine. 375:1592-1593.
    332. The Brave New World of clinical cancer research. Molecular Oncology. 9:951-959.
    333. Genetic diversity among U.S. sunflower inbreds and hybrids. Crop Science. 49:1295-1303.
    334. Bayesian perspectives on multiple comparisons. Journal of Statistical Planning and Inference. 82:215-227.
    335. Good practices for adaptive clinical trials in pharmaceutical product development. Drug Information Journal. 43:539-556.
    336. Floor discussion. Clinical Trials. 2:301-304.
    337. Bayesian methods in Phase III trials. Drug Information Journal. 25:345-368.
    338. Journal of the American Statistical Association. 69:485-491.
    339. Breast cancer heterogeneity may explain peaks in recurrence [2]. International Journal of Surgery. 3:287.
    340. Discussion of "multivariate bayesian logistic regression for analysis of clinical trial safety issues" by w. Dumouchel. Statistical Science. 27:344-345.
    341. In reply [12]. Journal of Clinical Oncology. 23:6804-6805.
    342. An improved procedure for selecting the better of two bernoulli populations. Journal of the American Statistical Association. 68:979-984.
    343. Bayesian Survival Analysis With Nonproportional Hazards Metanalysis of Combination Pravastatin-Aspirin. Journal of the American Statistical Association. 99:36-44.
    344. A response-adaptive design of initial therapy for emergency department patients with heart failure. Contemporary Clinical Trials. 52:46-53.
    345. Comment. Statistical Science. 9:253-255.
    346. The authors reply. New England Journal of Medicine. 361:1023-1024.
    347. Good Practices for Adaptive Clinical Trials in Pharmaceutical Product Development. Therapeutic Innovation and Regulatory Science. 43:539-556.
    348. Symmetrized percent change for treatment comparisons. American Statistician. 60:27-31.
    349. The authors reply [13]. New England Journal of Medicine. 358:198.
    350. Breast Cancer Research and Treatment. 160:297-304.
    351. Letters to the editor. American Statistician. 26:47.
    352. Attitudes and opinions regarding confirmatory adaptive clinical trials. Trials. 17.
    353. Screening mammography for women in their forties. Breast Disease. 10:23-32.
    354. The probability of a field goal. American Statistician. 39:152-155.
    355. Teaching Elementary Bayesian Statistics with Real Applications in Science. American Statistician. 51:241-246.
    356. Interim analysis in clinical trials; the role of the likelihood principle. American Statistician. 41:117-122.
    357. Maximizing the length of a success run for many-armed bandits. Stochastic Processes and their Applications. 15:317-325.
    358. Rejoinder. Statistical Science. 6:202-205.
    359. CNS Anticancer Drug Discovery and Development Conference White Paper. Neuro-Oncology. 17:vi1-vi26.
    360. The authors reply [13]. New England Journal of Medicine. 354:769.
    361. Erratum. Clinical Pharmacology and Therapeutics. 48:224.
    362. Advancing clinical trials to streamline drug development. Clinical Cancer Research. 21:4527-4535.
    363. Breast Cancer Working Group of the Cancer Intervention and Surveillance Modeling Network. Effects of mammography screening under different screening schedules. Annals of Internal Medicine. 152:136.
    364. Breast Cancer. 47-61.
    365. In reply [14]. Journal of Clinical Oncology. 23:8131-8132.
    366. Design of a Bayesian adaptive phase 2 proof-of-concept trial for BAN2401, a putative disease-modifying monoclonal antibody for the treatment of Alzheimer's disease. Alzheimer's and Dementia: Translational Research and Clinical Interventions. 2:1-12.
    367. Clinical trialist perspectives on the ethics of adaptive clinical trials. BMC Medical Ethics. 16.
    368. Simulation-based sequential Bayesian design. Journal of Statistical Planning and Inference. 137:3140-3150.
    369. In reply [8]. Journal of Clinical Oncology. 25:2634-2635.
    370. Risk of acute myeloid leukemia and myelodysplastic syndrome among older women receiving anthracycline-based adjuvant chemotherapy for breast cancer on Modern Cooperative Group Trials (Alliance A151511). Breast Cancer Research and Treatment. 161:363-373.
    371. Bayesian statistics and the efficiency and ethics of clinical trials. Statistical Science. 19:175-187.
    372. Bernoulli two-armed bandits with geometric termination. Stochastic Processes and their Applications. 11:35-45.
    373. Group sequential clinical trials. Journal of the American Statistical Association. 89:1528-1534.
    374. Interpreting adjuvant breast cancer data in 2006 and beyond. European Journal of Cancer, Supplement. 4:17-22.
    375. Regional Changes in Hormone Therapy Use and Breast Cancer Incidence in California From 2001 to 2004. Breast Diseases. 19:131-132.
    376. Adaptive dose-response studies. Drug Information Journal. 40:451-461.
    377. Comment. American Statistician. 68:88-89.
    378. Reflections on the adaptive designs accelerating promising trials into treatments (ADAPT-IT) process-Findings from a qualitative study. Clinical Research and Regulatory Affairs. 32:121-130.
    379. A class of optimal stopping problems for sampling without replacement. Biometrika. 61:361-368.
    380. Inferences using DNA profiling in forensic identification and paternity cases. Statistical Science. 6:175-189.
    381. Combining progression-free survival and overall survival as a novel composite endpoint for glioblastoma trials. Neuro-Oncology. 17:1106-1113.
    382. FDA recalls not as alarming as they seem. Archives of Internal Medicine. 171:1004-1005.
    383. Right-sizing adjuvant and neoadjuvant clinical trials in breast cancer. Clinical Cancer Research. 22:3-5.
    384. Accelerated approval of promising agents in the neoadjuvant setting. Breast Diseases. 24:126-128.
    BERRY's Networks
    Click the
    Explore
    buttons for more information and interactive visualizations!
    Concepts (680)
    Explore
    _
    Co-Authors (120)
    Explore
    _
    Similar People (60)
    Explore
    _
    Same Department Expand Description
    Explore
    _